Vitamin B12 deficiency …

Douglas J Lanska MD MS MSPH

General Neurology

Updated 05.24.2024
Released 10.06.1999
Expires For CME 05.24.2027

Vitamin B12 deficiency

Author: Douglas J Lanska MD MS MSPH

See Contributor Disclosures

Vitamin B12 deficiency

In This Article

Quick Link

Introduction

Overview

Vitamin B12 deficiency may cause an extraordinary variety of progressive neurologic syndromes. In this article, the author discusses the manifestations of vitamin B12 deficiency.

Key points

	• Vitamin B12 deficiency should be suspected in any patient with otherwise unexplained peripheral neuropathy, myelopathy, optic neuropathy, dementia, ataxia, movement disorder, or psychiatric disturbance and in individuals with macrocytosis with or without anemia.
	• Serum B12 level should be determined in any patient with suspected vitamin B12 deficiency.
	• Abnormal red blood cell indices are neither sensitive nor specific for vitamin B12 deficiency.
	• In cases of borderline low vitamin B12 levels, or when vitamin B12 deficiency is strongly suspected despite reported normal levels from an automated assay, elevated serum methylmalonic acid and homocysteine levels may confirm a physiological deficiency, as may a normalization of these levels with B12 repletion.
	• Daily, high-dose oral vitamin B12 supplementation appears as effective as parenteral therapy and is substantially less costly. This has really only been tested, though, in minimally symptomatic or asymptomatic patients. A brief parenteral course of therapy may still be needed for patients with significant neurologic signs of vitamin B12 deficiency.

Historical note and terminology

At a meeting of the South London Medical Society in 1849, and subsequently, in a monograph in 1855, British physician Thomas Addison (1793–1860) at Guy’s Hospital in London described several cases with “idiopathic” anemia characterized by pallor, weakness, and progressively worsening health leading to death (109). Later this condition was called Addisonian anemia, at least until German internist Michael Anton Biermer (1827-1892) in Zurich named it perniciöse Anämie (ie, pernicious or fatal anemia) when describing 15 cases of severe anemia (of mixed etiologies) in 1872 (109).

British physician Thomas Addison

British physician Thomas Addison (1793-1860) described several cases with “idiopathic” anemia characterized by pallor, weakness, and progressively worsening health leading to death. (Courtesy of the Wellcome Collection. Creativ...
German internist Michael Anton Biermer

In 1872, German internist Michael Anton Biermer (1827-1892) named a condition pernicioÌse AnaÌmie (ie, pernicious or fatal anemia) when describing 15 cases of severe anemia (of mixed etiologies). (Courtesy of Wikimedia Commons. Pu...

Although pernicious anemia, or Addison-Biermer disease, had been recognized clinically in the mid-19th century, the associated neurologic, gastrointestinal, and hematologic manifestations were not recognized clinically and linked with pernicious anemia until the end of the 19th century (109).

In 1884, Lichtenstein described cases of pernicious anemia with neurologic manifestations felt to be suggestive of tabes dorsalis (109). The first accurate description of spinal cord pathology associated with certain types of anemia was by German physician Ludwig Lichtheim (1845-1926), who described three cases, two with autopsy (118). Similar cases were reported by a number of authors over the next several decades (109). Guyanese-British neurologist James Samuel Risien Russell (1863-1939) and colleagues coined the term "subacute combined degeneration of the spinal cord" in their study of the neuropathological abnormalities commonly associated with pernicious anemia (175).

German physician Ludwig Lichtheim

German physician Ludwig Lichtheim (1845-1926) provided the first accurate description of spinal cord pathology associated with certain types of anemia. (Photograph c1890. Courtesy of the U.S. National Library of Medicine. Public d...
Guyanese-British neurologist James Samuel Risien Russell

In 1900, Guyanese-British neurologist James Samuel Risien Russell (1863-1939) and colleagues coined the term "subacute combined degeneration of the spinal cord" in their study of the neuropathological abnormalities commonly ass...

In 1870, British gastroenterologist Samuel Fenwick (1821-1902) in London associated stomach atrophy with this form of anemia and demonstrated that stomach mucosa from an affected fresh cadaver could not digest boiled egg white with prolonged incubation, whereas mucosa from a control stomach could do this (109). Subsequently, German internist Arnold Cahn (1858-1927) and German physician and physiologist Josef Freiher von Mering (1849-1908), working in the Strassburg clinic of German physician Adolf Kußmaul (1822-1902), showed that a patient with pernicious anemia had no hydrochloric acid in the stomach contents, a finding later demonstrated to be pervasive in this disorder and to precede the development of anemia (109).

British gastroenterologist Samuel Fenwick

British gastroenterologist Samuel Fenwick (1821-1902) associated stomach atrophy with this form of anemia and demonstrated that stomach mucosa from an affected fresh cadaver could not digest boiled egg white with prolonged incu...
German physician and physiologist Josef Freiher von Mering

German physician and physiologist Josef Freiher von Mering (1849-1908) showed that a patient with pernicious anemia had no hydrochloric acid in the stomach contents. (Courtesy of the U.S. National Library of Medicine. Public domai...

It was not until the 1850s--after Addison’s original communication--that the first red cell counts were done by German physiologist Karl von Vierordt (1818-1884) and that hemoglobin was discovered by German physiologist Otto Funke (1828-1879) (109). In 1875, American physician and educator William Pepper Jr. (1843-1898), then a lecturer in clinical medicine at the University of Pennsylvania in Philadelphia (and subsequently Professor of Clinical Medicine, Professor of the Theory and Practice of Medicine, and the longtime Provost of the university), noted the extreme hyperplasia of the bone marrow in patients with pernicious anemia (109). In 1880, German physician-scientist (and later Nobel laureate) Paul Ehrlich (1854-1915), using aniline dyes developed by his cousin Carl Weigert (1845-1904), a German pathologist, identified large erythroid precursor cells that he called “megaloblasts” in stained blood smears of patients with pernicious anemia (109). Subsequent hematologists noted characteristics of megaloblastic anemia in the peripheral blood (ie, macrocytes, poikilocytes, and hypersegmented neutrophils) and bone marrow (eg, megaloblasts, meta-myelocytes, and megakaryocytes) (109). Later, American physician-scientist Francis Weld Peabody (1881-1927) of the Thorndike Memorial Laboratory in Boston hypothesized that this macrocytic anemia was due to maturational arrest of erythroblasts in the bone marrow (109).

American physician and educator William Pepper Jr.

In 1875, American physician and educator William Pepper Jr. (1843-1898) noted the extreme hyperplasia of the bone marrow in patients with pernicious anemia. (Courtesy of the U.S. National Library of Medicine. Photograph restored b...
German physician-scientist and Nobel laureate Paul Ehrlich

In 1880, German physician-scientist (and later Nobel laureate) Paul Ehrlich (1854-1915) identified large erythroid precursor cells that he called “megaloblasts” in stained blood smears of patients with pernicious anemia. (Photo...

In 1925, American medical researcher George Minot (1885-1950), at Peter Bent Brigham Hospital in Boston, and American physician William Parry Murphy (1892-1987) at the Collis P Huntington Memorial Hospital of Harvard University, hospitalized a group of patients with pernicious anemia to systematically assess liver as a treatment (109). By 1926, Minot and Murphy reported clinical and hematological improvement in 45 patients with pernicious anemia treated with a dietary regimen that incorporated large quantities of liver (Minot and Murphy 1926; 109). The patients improved clinically, often dramatically so, in conjunction with improvements in their hematological indices. This suggested that a factor present in calf liver could rapidly restore red blood cell counts in pernicious anemia. Moreover, this clinical improvement could be sustained for many years, well beyond the previous life expectancy of such patients. Patients with relatively mild neurologic dysfunction also improved, but patients with more severe neurologic dysfunction showed, at best, slow and limited improvement. Eventually, with Edwin J Cohn, a physical chemist in the Laboratories of Physiology at Harvard Medical School, they tried to isolate the active principle in the liver, which resulted in clinical improvement; although they were not successful in isolating the responsible factor in liver, they did demonstrate that potent extracts could be given parenterally in very small quantities. In 1934, Minot and Murphy were awarded the Nobel Prize for their discovery of a treatment for pernicious anemia.

American physician and Nobel laureate William Parry Murphy

In 1926, American physician William Parry Murphy (1892-1987) with George Minot (1885-1950) reported the clinical and hematological improvement in 45 patients with pernicious anemia treated with a dietary regimen that incorporated ...

In 1926, after Minot and Murphy’s success with liver therapy for pernicious anemia, William Bosworth Castle (1897-1990), then an assistant resident at the Thorndike Memorial Laboratory of Boston City Hospital (which had recently come under the direction of Minot as successor to Francis Peabody), decided to pursue his belief that gastric achlorhydria (“achylia gastrica”) was etiologically linked to pernicious anemia (109). Castle noted that: (1) gastric achlorhydria precedes the other clinical manifestations of pernicious anemia, and (2) even when the blood of a patient with pernicious anemia is returned to normal with liver feeding, gastric achlorhydria persisted (109). Castle suggested that some essential step of gastric digestion was impaired, thereby disrupting absorption of an essential dietary factor. He reasoned that this defective process might be circumvented by utilizing gastric juices from individuals with normal stomachs. By an ingenious series of experiments, Castle and his colleagues showed that indeed the normal stomach secretes a substance separate from normal gastric juice that is able to interact with a dietary substance to promptly relieve the anemia of these patients. Castle later labeled the essential substance secreted by a normal stomach as “intrinsic factor” and the substance present in food as “extrinsic factor.” Subsequent studies showed that intrinsic factor serves as an intestinal transport vehicle for extrinsic factor (later identified as vitamin B12) (109).

Cyanocobalamin (vitamin B12) was finally isolated by the mid-20th century, and this greatly improved the treatment of pernicious anemia and the associated neurologic manifestations (109). By 1955, British chemist Dorothy Crowfoot Hodgkin (1910-1994) of Cambridge University determined the molecular structure of cyanocobalamin using computer-assisted x-ray crystallography, work for which she received the 1964 Nobel Prize in Chemistry (109). The complex structure of vitamin B12 included a single cobalt atom at the center of a tetrapyrrole or “corrin” macro-ring structure. A complete chemical synthesis of vitamin B12 was finally achieved in 1960 by an international consortium of chemists.

British chemist and Nobel laureate Dorothy Crowfoot Hodgkin

British chemist Dorothy Crowfoot Hodgkin (1910-1994) determined the molecular structure of cyanocobalamin using computer-assisted x-ray crystallography, work for which she received the 1964 Nobel Prize in Chemistry. (Courtesy o...

Subsequent biochemical work demonstrated that only two enzyme systems require forms of vitamin B12 in man: adenosylcobalamin in the conversion of methylmalonyl coenzyme A to succinyl coenzyme A by methylmalonyl-coenzyme A mutase, and methylcobalamin in the conversion of homocysteine to methionine by methionine synthase (109).

In the late 1950s, studies showed that there are two mechanisms involved in vitamin B12 absorption. With physiologic (ie, 1 to 2 mg) doses of oral vitamin B12, the vitamin is absorbed by a process dependent on intrinsic factor; but with much larger oral doses, vitamin B12 appears in plasma much sooner as a result of passive diffusion, independent of the presence or absence of intrinsic factor. When vitamin B12 is released from foods by peptic digestion, it is bound to intrinsic factor, affording partial protection against gut microorganisms and parasites during transport through the gut to the terminal ileum, where the complex binds to microvilli of the intestinal epithelial cells.

Beginning in the late 1950s and continuing through the 1960s, several lines of evidence converged in support of an autoimmune basis for pernicious anemia: (1) corticosteroids improve vitamin B12 absorption and reduce anemia; (2) gastric and serum autoantibodies to intrinsic factor and gastric parietal cells are present in the majority of patients; and (3) other autoimmune diseases (eg, Hashimoto thyroiditis, insulin-dependent diabetes mellitus, Addison disease, and vitiligo) are common in such patients (109).

Pernicious anemia is now understood to be fundamentally an autoimmune disorder that begins with an autoimmune gastritis in which antiparietal cell antibodies produce atrophic gastritis with a resultant decline in intrinsic factor production, evolving over years or even decades (109). In 1988, the principal target of these antibodies was identified by Swedish internist F Anders Karlsson and colleagues as the acid-producing H+/ K+-adenosine triphosphatase (ATPase) in the cell membrane of gastric parietal cells (96).

Clinical manifestations

Presentation and course

	• Vitamin B12 deficiency typically presents with either hematologic or neurologic signs.
	• The hematologic and neurologic signs associated with vitamin B12 deficiency may be dissociated.
	• Well-recognized neurologic manifestations of vitamin B12 deficiency include myelopathy, peripheral polyneuropathy, optic neuropathy, psychiatric disturbances, and dementia.
	• Subacute combined degeneration of the spinal cord refers to progressive degeneration of both the corticospinal (lateral column) and dorsal column tracts of the spinal cord.
	• When present, the hematologic manifestations of vitamin B12 deficiency include macrocytic anemia, hyper-segmentation of neutrophil nuclei, neutropenia, and megaloblastic changes in the bone marrow.
	• Hematologic abnormalities in the peripheral blood are insensitive indicators of even severe and neurologically symptomatic vitamin B12 deficiency.

Vitamin B12 deficiency typically presents with either hematologic or neurologic signs. A curious feature of the condition is that the hematologic and neurologic signs may be dissociated. In fact, in one large series, the severity of the neurologic deficits correlated inversely with the degree of anemia and macrocytosis (74). There may also be cutaneous manifestations of vitamin B12 deficiency and additional manifestations associated with the underlying causes of the vitamin B12 deficiency.

Neurologic manifestations. Neurologic deficits are common in vitamin B12 deficiency. In one large study, 39% of patients with deficiency had neurologic manifestations, and in almost 80% of these cases, the neurologic symptoms were the sole or dominant manifestation of the deficiency (74). Well-recognized neurologic manifestations include myelopathy, peripheral polyneuropathy, optic neuropathy, psychiatric disturbances, and dementia.

Subacute combined degeneration of the spinal cord. This syndrome is so named because it may cause progressive degeneration of both the corticospinal (lateral column) and dorsal column tracts of the spinal cord. Typically, the neurologic syndrome evolves over a period of several months, although the disease may take a more chronic course. The most common early sign is paresthesias, which usually occurs first in the distal lower extremities. At this early stage, there may be no objective abnormalities on the neurologic examination. Later, signs and symptoms of a myelopathy involving the dorsal and lateral columns combined with a peripheral neuropathy may develop, but overt spasticity is uncommon (74). Initial ambulatory function is a useful clinical marker of the severity of spinal cord dysfunction and may be a useful predictor of final functional outcome (86). Impaired vibration and joint position sense are found on examination. The patient may be ataxic. Weakness is less common. Vitamin B12 deficiency only infrequently results in incontinence of bladder or bowel, impotence, or orthostatic hypotension.

Subacute combined degeneration of the spinal cord

Photomicrograph of a section of spinal cord, obtained at autopsy, which revealed subacute degeneration (pallor) of both the dorsal and lateral columns of the cord, which characteristically encountered with vitamin B12 deficiency. ...

Peripheral polyneuropathy. Vitamin B12 deficiency is a frequently recognized cause of distal symmetric axonal polyneuropathy, and it should be screened for in all patients presenting with polyneuropathy. Although commonly encountered in primary care, vitamin B12 deficiency may also be identified in patients previously deemed as having an idiopathic neuropathy seeking evaluation in a tertiary care center (60).

Uncommon neurologic manifestations. Rarely, vitamin B12 deficiency will manifest as a movement disorder, such as parkinsonism, focal dystonia, chorea, or blepharospasm (151; 01; 56; 181). Rarer still are reports of seizures in vitamin B12 deficiency (52; 139; 142). Several small studies suggest that dysautonomic syndromes, such as orthostatic hypotension, postural orthostatic tachycardia syndrome (POTS), and syncope are associated with vitamin B12 deficiency and may be improved by vitamin B12 therapy (24; 137; 148); however, dramatic dysautonomia does not appear to be a prominent manifestation of deficiency. Vitamin B12 deficiency may contribute to hearing impairment at low frequencies (0.25 to 4 kHz) in children, whereas pure-tone hearing thresholds from 8 to 16 kHz do not seem to be affected (05).

Infantile vitamin B12 deficiency. In Norway, where 5% to 10% of neonates and infants have biomarkers suggesting vitamin B12 deficiency from newborn screening tests and unselected clinical screening, spells, tremor, and irritability are common findings in early infant vitamin B12 deficiency (124). Nitrous oxide given during labor may be a contributing risk factor (124).

In a prospective study of 252 Norwegian infants aged 3 to 7 months, 46% had hyperhomocysteinemia, and 10% had hyperhomocysteinemia combined with clinically relevant symptoms suggestive of B12 deficiency (123); hyperhomocysteinemia was associated with tremor and excessive sleep, even though most infants with hyperhomocysteinemia did not show symptoms.

Ophthalmologic manifestations. An unusual but well-documented manifestation of cobalamin deficiency is optic neuropathy. This may present as a subacute progressive decrease in visual acuity with a cecocentral scotoma (ie, a scotoma obscuring central vision and enlarging the blind spot). Vitamin B12 deficiency may present with a maculopathy similar to age-related macular degeneration, and it has been suggested that a relative deficiency may also play a role in age-related macular degeneration (AMD), the most common cause of blindness or low vision in older adults (51).

Dementia and neuropsychiatric manifestations. Severe vitamin B12 deficiency causes psychiatric and cognitive disturbances in some patients. The abnormalities are not specific and can range from depression or mild memory impairment to global dementia. Usually, these occur along with other neurologic deficits such as a myelopathy or neuropathy. It is uncertain whether mild or moderate vitamin B12 deficiency can cause dementia.

Uncommonly, vitamin B12 deficiency will present with prominent psychiatric manifestations. Psychosis has been reported several times (52).

Neurologic outcomes in infants and children. Cobalamin deficiency may occur in infants whose mothers are cobalamin deficient or in those with rare inherited conditions such as Imerslund-Grasbeck syndrome (see Etiology section). Maternal vitamin B12 deficiency, exclusive breastfeeding, and a maternal diet low in vitamin B12 are associated with infant vitamin B12 deficiency, methylmalonic acidemia, and homocysteinemia (216).

Severe cobalamin deficiency in infancy presents as developmental regression. A severe cobalamin-deficiency neuropathy may result in "floppy infant" syndrome (168). Infantile spasms and West syndrome (developmental delay, infantile spasms, and hypsarrhythmia) have been reported to be potential outcomes of infantile dietary vitamin B12 deficiency (58; 127; 180). Myoclonus, tremor, or seizures may occur on initiation of vitamin B12 therapy in severely deficient infants; these conditions improve with continued vitamin B12 treatment (69; 70; 150; 27; 149). Infants and children who have experienced neurologic manifestations of vitamin B12 deficiency may be left with long-term neurologic impairment (209; 225; 196).

Non-neurologic manifestations. When present, the hematologic manifestations of vitamin B12 deficiency include macrocytic anemia with macro-ovalocytes and macro-erythrocytes (or macrocytes), hypersegmentation of neutrophil nuclei, neutropenia, and megaloblastic changes in the bone marrow. However, hematologic abnormalities in the peripheral blood are insensitive indicators of even severe and neurologically symptomatic vitamin B12 deficiency (74; 15). Severe vitamin B12 deficiency may cause a thrombotic microangiopathy resembling thrombotic thrombocytopenic purpura (147).

Macro-ovalocytes

Peripheral blood smear of a patient with pernicious anemia showing many macro-ovalocytes (Leishman stain, 100X, oil immersion). (Source: Ramanathan S, Karunakaran P, Mohamed KS, Kini R, Thangavel P, Ananthavadivelu M. A rare ca...
Macroerythrocyte or macrocyte

Under a magnification of 1000X, this photomicrograph reveals the presence of a macroerythrocyte, or macrocyte, an enlarged erythrocyte (arrowhead), which is seen in macocytosis resulting from vitamin B12 deficiency. (Photomicrogra...
Hypersegmented neutrophil

Peripheral blood smear showing a hypersegmented neutrophil. (Photomicrograph by Dr. Gabriel Caponetti 2014. Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 4.0 International License.)
Hypersegmented neutrophils

Peripheral blood smear showing two hypersegmented neutrophils. (Photomicrography by Professor Osaro Erhabor. Courtesy of Wikimedia Commons. Creative Commons Attribution-Share Alike 4.0 International license.)
Bone marrow in pernicious anemia

This photomicrograph reveals typical histopathologic details exhibited by a bone marrow tissue sample indicative of megaloblastic anemia as seen in pernicious anemia. Pernicious anemia is the result of an autoimmune disease in whi...

Gastrointestinal disorders that can be associated with vitamin B12 deficiency include atrophic gastritis, particularly in patients with pernicious anemia. Upper gastrointestinal endoscopy in atrophic gastritis shows a shiny surface and pale gastric mucosa with effacement of the gastric rugal (mucosal) folds, along with prominent submucosal vessels (164). Histopathological examination of biopsy tissue from body and fundus of a patient with pernicious anemia may show areas of atrophy and a reduction in the number of glands, which are replaced by sheets of chronic inflammatory cells and fibrosis (164). In severe cases, a pan-enteropathy is present with diarrhea and malabsorption of nutrients. Rarely, jaundice occurs due to impaired erythropoiesis (49).

Endoscopic appearance of atrophic gastritis

(Source: Ramanathan S, Karunakaran P, Mohamed KS, Kini R, Thangavel P, Ananthavadivelu M. A rare case of autoimmune gastritis and pernicious anemia associated with vitiligo. J Case Reports 2017;7[2]:200-3. Creative Commons Attr...
Gastric biopsy in a patient with pernicious anemia

Histopathological examination of the biopsy tissue from body and fundus of a patient with pernicious anemia showed bits of gastric mucosa with areas of atrophy and a reduction in the number of glands, which were replaced by the...

Cutaneous manifestations of cobalamin deficiency include most commonly hyperpigmentation but also hair and nail changes; oral changes (eg, atrophic glossitis or a "beefy red" tongue), and vitiligo (typically in association with pernicious anemia or autoimmune atrophic gastritis, specifically) (136; 25; 194; 205; 95; 177; 179; 178; 34; 153; 164; 203; 220; 43; 221).

Extensive linear or band-like “beefy red” patches on the dorsum and margins of the tongue in a patient with vitamin B12 deficiency (1)

(Source:Xu X, Liu Y, Xiong X, et al. Diagnostic value of oral "beefy red" patch combined with fingertip blood mean corpuscular volume in vitamin B12 deficiency. BMC Oral Health 2022;22[1]:273. Creative Commons Attribution 4.0 I...
Extensive linear or band-like “beefy red” patches on the dorsum and margins of the tongue in a patient with vitamin B12 deficiency (2)

(Source:Xu X, Liu Y, Xiong X, et al. Diagnostic value of oral "beefy red" patch combined with fingertip blood mean corpuscular volume in vitamin B12 deficiency. BMC Oral Health 2022;22[1]:273. Creative Commons Attribution 4.0 I...
Localized “beefy red” patches on the underside of the tongue in a patient with vitamin B12 deficiency

(Source:Xu X, Liu Y, Xiong X, et al. Diagnostic value of oral "beefy red" patch combined with fingertip blood mean corpuscular volume in vitamin B12 deficiency. BMC Oral Health 2022;22[1]:273. Creative Commons Attribution 4.0 I...
Ulcer on the ventral region of the tongue in a patient with vitamin B12 deficiency

(Source:Xu X, Liu Y, Xiong X, et al. Diagnostic value of oral "beefy red" patch combined with fingertip blood mean corpuscular volume in vitamin B12 deficiency. BMC Oral Health 2022;22[1]:273. Creative Commons Attribution 4.0 I...
Partial atrophic glossitis

Partial atrophic glossitis in a 58-year-old woman with the chief complaint of a burning sensation on the tongue for 6 months. She was easily fatigued for several months and denied any systemic diseases. Her serum vitamin B12 le...
Complete atrophic glossitis

Complete atrophic glossitis in a 46-year-old woman with the chief complaint of glossodynia for approximately 1 year. She denied any systemic diseases. Her serum levels of vitamin B12 and ferritin were 94 ng/L (normal range 180 ...

Skin hyperpigmentation is typically seen on the hands and feet, but it can occur anywhere (130).

Atrophic glossitis

This patient displayed moderate filiform taste bud atrophy, which was thought to be due to a vitamin B12 deficiency. A nutritional deficiency in vitamin B12 or iron will cause the tongue to undergo atrophic changes in its taste bu...
Cutaneous changes in pernicious anemia

Cutaneous changes in pernicious anemia: (A) vitiligo patches around the eyes; (B) graying of scalp hairs in the occipital region; (C, D) vitiligo patches in right chest and left thigh. (Source: Ramanathan S, Karunakaran P, Moha...
Cutaneous hyperpigmentation in woman with vitamin B12 deficiency and pernicious anemia

A 52-year-old Indian woman with megaloblastic anemia and peculiar cutaneous hyperpigmentation (prior to therapy). Photo shows diffuse, brownish-black discoloration of the palms (A1) and knuckle pad hyperpigmentation in the dors...
Reversal of hyperpigmentation in woman with vitamin B12 deficiency and pernicious anemia after initiation of parenteral cyanocobalamin therapy

Resolution of hyperpigmentation on the palms (B1) and dorsum of the hands (B2) 12 weeks after initiation of parenteral cyanocobalamin therapy. (Source: Padhi S, Sarangi R, Ramdas A, et al. Cutaneous hyperpigmentation in megalob...
Cutaneous hyperpigmentation in man with megaloblastic anemia

Photos of 52-year-old vegetarian Indian man with diffuse brownish-black pigmentation over dorsal aspect of feet (C1) and dusky, brownish-black discoloration of palms with accentuation of palmar creases (C2). Laboratory studies ...

Hyperpigmentation and glossitis may resolve with vitamin B12 replacement (153).

Prognosis and complications

Left untreated, pernicious anemia and other causes of severe vitamin B12 deficiency are fatal. Fatal cases are marked by severe myelopathy, encephalopathy, or anemia. Neurologic manifestations may not reverse with vitamin B12 therapy, so prompt recognition and treatment are needed to avoid permanent disability.

Pernicious anemia is also associated with an increased risk of carcinoid tumors and carcinoma of the stomach (188). Endoscopic screening for gastric cancer may be warranted in patients diagnosed with pernicious anemia (10).

Clinical vignette

A 41-year-old woman was referred for headaches and numbness in the extremities. She first noted tingling paresthesias approximately 9 months earlier, beginning simultaneously in the feet and hands. Her past history was notable for migraine headaches and hypothyroidism; she had been on thyroid replacement therapy for 16 years. Her only prescription medication was thyroxin 125 µg daily. On examination, she appeared depressed and anxious. Cranial nerve and motor examinations were normal. There was mild difficulty with tandem walking, but the examiner perceived possible embellishment. Tendon reflexes were normal. Vibration sense was reduced in the great toes bilaterally, but sensory examination was otherwise normal. Romberg sign was absent. Laboratory results included a normal thyroid-stimulating hormone level, normal hemoglobin A1c, and negative syphilis serology. Hematocrit and mean corpuscular volume were normal. A vitamin B12 level was 150 pg/ml (radioimmunoassay). Methylmalonic acid was elevated at 3500 nM/L. The patient was given cyanocobalamin 1 mg intramuscularly daily for 5 days (as an outpatient) and then maintained on 1 mg intramuscularly monthly. Her paresthesias and mild gait instability resolved within a month of initiating therapy. Vibration sense returned in the toes.

Biological basis

	• Cobalamin participates as a cofactor in only two enzymatic reactions in humans: (1) conversion of homocysteine to methionine; (2) conversion of methylmalonyl-CoA to succinyl-CoA.
	• Humans are completely dependent on dietary sources for cobalamin.
	• Virtually all dietary cobalamin comes from meat or dairy products.
	• Cobalamin is transported through the gastrointestinal system by carrier proteins (haptocorrin and intrinsic factor) until it is eventually taken up by receptor-mediated endocytosis in the terminal ileum.
	• The carrier protein called "intrinsic factor" is a glycoprotein produced by gastric parietal cells. Intrinsic factor is necessary for receptor-mediated endocytosis in the terminal ileum.
	• In the blood, cobalamin is also transported by carrier proteins, with the physiologically important fraction bound to the carrier protein transcobalamin II.
	• Disturbances at any step of cobalamin metabolism may result in deficiency, but pernicious anemia accounts for greater than 90% of cases of symptomatic vitamin B12 deficiency, and most other symptomatic cases are due to other intrinsic factor-related sources of vitamin B12 malabsorption.
	• Pernicious anemia is the result of an autoimmune gastritis in which the principal antigenic target is the H/K ATPase of gastric parietal cells.
	• A deficiency in vitamin B12 is the most common nutritional deficiency in patients who have had gastric bypass surgery. Gastrectomy increases the risk of deficiency because parietal cells, the source of intrinsic factor, are removed.
	• Pathology of the distal ileum (eg, from regional enteritis, Whipple disease, ileal tuberculosis, tropical sprue, and surgical resection of the distal ileum), where vitamin B12 is normally absorbed, may impair absorption of the intrinsic factor-cobalamin complex.
	• Cobalamin deficiency is common in vegans, occurring in up to half of these individuals who do not receive vitamin B12 supplementation.
	• Because nitrous oxide irreversibly oxidizes the cobalt in cobalamin, a functional deficiency of cobalamin can be caused by inhalation of nitrous oxide, either as an anesthetic agent or as a recreational drug.

Etiology and pathogenesis

Cobalamin. Cobalamin is a complex molecule at the core of which is a corrin ring: a tetrapyrrole structurally homologous to heme but with a cobalt atom, rather than iron, at its center.

Cobalamin (vitamin B12)

Cobalamin is a complex molecule at the core of which is a corrin ring: a tetrapyrrole structurally homologous to heme but with a cobalt atom, rather than iron, at its center. This illustration shows the chemical structures of v...

Cobalamin is known to participate in only two enzymatic reactions in humans (120).

Simplified scheme of the two metabolic pathways that use cobalamin cofactors

Legend: AdoCbl, adenosylcobalamin; Cys, cystine; Cyst, cystathionine; Hcy, homocysteine; MeCbl, methyladenosylcobalamin; Met cycle, methionine cycle; MCM, methylmalonyl-CoA mutase; MMA, methylmalonic acid; MS, methionine syntha...

First, it is an essential cofactor for the conversion of homocysteine to methionine by the enzyme methionine synthase (MTR), or more precisely, the regeneration of methionine from homocysteine. Second, cobalamin is an essential cofactor for the conversion of methylmalonyl-CoA to succinyl-CoA by the enzyme methylmalonyl-CoA mutase (MUT). Cobalamin is not known to participate in DNA synthesis, but folate, as 5,10-methylene tetrahydrofolate, is essential for the synthesis of purines.

Methionine synthase reaction

Methionine synthase reaction. Legend: 5-methyltetrahydrofolate (5-MTHF); tetrahydrofolate (THF); homocysteine (Hcy); methionine (Met). (Courtesy of Wikimedia Commons. Modified by Dr. Douglas Lanska. Creative Commons Attribution...
Methionine synthase reaction, showing the transfer of a methyl group

Methionine synthase reaction, showing the transfer of a methyl group from 5-methyltetrahydrofolate (5-MTHF) to cobalamin and then to homocysteine to form methionine. (Illustration by Boghog 2019. Courtesy of Wikimedia Commons. ...
Methylmalonyl-CoA mutase reaction

Methylmalonyl-CoA mutase reaction. (Courtesy of Wikipedia. Modified by Dr. Douglas Lanska.)

In the cytoplasm, vitamin B12 deficiency impacts the enzyme methionine synthase, with some consequences that adversely affect DNA, RNA, proteins, neurotransmitters, and phospholipids, and with some consequences that indirectly contribute to oxidative stress.

Metabolic consequence of vitamin B12 deficiency in the cytoplasm

In the cytoplasm, vitamin B12 deficiency impacts the enzyme methionine synthase (MTR). This deficiency not only disrupts the biosynthesis of crucial compounds but also triggers the accumulation of reaction intermediates that ar...

In mitochondria, vitamin B12 deficiency impacts the enzyme L-methylmalonyl-CoA mutase (MUT) with some consequences that adversely affect lipogenesis, as well as histone and DNA methylations processes.

Metabolic consequence of vitamin B12 deficiency in the mitochondria

In mitochondria, vitamin B12 deficiency impacts the enzyme L-methylmalonyl-CoA mutase (MUT). This deficiency not only disrupts the biosynthesis of crucial compounds but also triggers the accumulation of reaction intermediates t...

Humans are completely dependent on dietary sources for cobalamin, with a minimum daily requirement of about 2.5 µg and a recommended intake of 6 µg daily. A typical American diet provides about 20 µg daily. Virtually all dietary cobalamin comes from meat or dairy products.

Absorption and metabolism of cobalamin. In humans, the uptake and transport of vitamin B12 (cobalamin) is a multi-step process, starting in the stomach, where the acidic environment facilitates the release of cobalamin from dietary proteins; this allows cobalamin to bind to a group of cobalamin-binding glycoproteins (salivary haptocorrin or "R binder”) that are produced in saliva.

Key mechanisms regarding the absorption, storage, and intracellular metabolism of vitamin B12 in human beings

Abbreviations: Ado-VitB12, adenosylcobalamin, also more fully 5′-deoxyadenosylcobalamin; Cubam R, cubam receptor, a multi-ligand receptor located in the terminal ileum, specializing in absorption of vitamin B12; FA, folic acid;...
Abstract of the metabolic processes and uptake mechanisms of vitamin B12 in humans

The arrows in the "metabolism" part of the figure indicate an increase (if pointing upwards) or a decrease (if pointing downwards) in the metabolite or vitamin B12.

Abbreviations: HC, haptocorrin (probably more co...

The haptocorrin group of immunologically cross-reacting proteins includes transcobalamins I and III. The glycosylated structure of haptocorrin protein conferring resistance to the acidic environment of the stomach (82).

The presence of food in the stomach also stimulates secretion of "intrinsic factor," a glycoprotein produced by gastric parietal cells. In the neutral pH of the duodenum, intrinsic factor displaces salivary haptocorrin with the aid of pancreatic enzymes. The "cobalamin-intrinsic factor" complex protects cobalamin from destruction until it is absorbed) passes through the small intestine.

In the terminal ileum, the cobalamin-intrinsic factor complex is specifically recognized by the cubam receptor on the apical surface of enterocytes, triggering receptor-mediated endocytosis. The complex is transported to lysosomes for further processing, and the cubam receptor is recycled (62). Cubam is a multifaceted complex that is comprised of two essential components, cubilin (CUB) and amnionless (AMN) (158; 161): cubilin is a cell receptor, which is essential for recognizing the " cobalamin-intrinsic factor" complex, whereas amnionless is involved in the receptor mediated endocytosis of the complex into enterocytes in the ileum. Once the cobalamin-intrinsic factor complex reaches the lysosomes, intrinsic factor undergoes degradation, thereby releasing free cobalamin, which is then actively transported into the cytoplasm with the help of two transmembrane proteins (46). In the cytoplasm, free cobalamin is conveyed through the basolateral side of enterocytes via active transport (mediated by multi-specific membrane transporter, multidrug-resistant protein 1, MRP1/ABCC1) or passive transport to the blood flow.

In the blood, cobalamin can bind with varying degrees of affinity to the known carriers, transcobalamin (previously named transcobalamin II) and haptocorrin. Cobalamin bound to transcobalamin (forming holotranscobalamin) represents the circulating bioavailable form of vitamin B12, which is subsequently absorbed by peripheral cells via endocytosis mediated by the receptor CD320 (also known as the transcobalamin II receptor), a ubiquitous cell surface receptor of the LDLR family (06). Following receptor-mediated endocytosis within lysosomes of peripheral target cells, transcobalamin is degraded, the CD320 receptor is recycled to the plasma membrane, and cobalamin, no longer complexed to a protein, can enter the cytoplasm via lysosomal transporters for utilization by the enzymes methionine synthase (MTR) and L-methylmalonyl-CoA mutase (MUT) (and may even be exported) (144).

In the blood, about 80% of cobalamin is bound to haptocorrin, forming holohaptocorrin, a complex that has a dual function: (1) holohaptocorrin conveys cobalamin to the liver, where it taken up through endocytosis (mediated by asialoglycoprotein receptor, ASGPR); and (2) cobalamin from holohaptocorrin can be transferred to transcobalamin, for which it has a higher affinity (131). Thus, holohaptocorrin is not only involved in the formation of the hepatic store of vitamin B12, it is itself a reserve of circulating vitamin B12 (131).

Metabolic consequences of cobalamin deficiency. In states of cobalamin deficiency, homocysteine and methylmalonic acid levels rise in the blood. How impairment of the two cobalamin-dependent reactions leads to the particular syndromes associated with deficiency is not completely understood. The hematologic and gastrointestinal abnormalities in cobalamin deficiency are similar to those of isolated folate deficiency and are generally attributable to impairment of DNA synthesis in the rapidly dividing cells of the gastrointestinal tract and bone marrow.

The failure of methionine synthesis due to cobalamin deficiency may either (1) lead to an accumulation of 5-methyl-tetrahydrofolate, trapping folate in a chemical form unusable in purine synthesis (the "folate trap" hypothesis) or (2) impair methylation reactions needed to produce formyl-tetrahydrofolate, a precursor to 5,10-methylene tetrahydrofolate. Whatever the mechanism, the impairment of DNA synthesis can be circumvented by the administration of sufficient amounts of exogenous folate. Thus, the hematologic and gastrointestinal effects of cobalamin deficiency are reversed by folate supplementation.

In contrast, it would appear that the neurologic effects of cobalamin deficiency are due to metabolic disturbances unrelated to purine synthesis because the neurologic deficits may develop independently of the hematologic abnormalities, and folate supplementation will not prevent or reverse these deficits. The exact mechanism of neurologic damage in vitamin B12 deficiency remains obscure, but disruption of normal myelin function appears to be important. Impaired methionine synthesis may lead to a depletion of S-adenosylmethionine, required for the synthesis of myelin phospholipids. Alternatively, accumulated methylmalonate and methylpropionate, precursors of the cobalamin-dependent synthesis of succinyl-CoA, may be incorporated abnormally into branched-chain fatty acids, resulting in abnormal myelination (71).

Causes of cobalamin deficiency. Disturbances at any step of cobalamin metabolism may result in actual or functional deficiency, but pernicious anemia accounts for the majority of cases of symptomatic vitamin B12 deficiency.

Pernicious anemia. Pernicious anemia is the result of an autoimmune gastritis in which the principal antigenic target is the H/K ATPase of gastric parietal cells. Gastric infection with H. pylori may trigger the underlying autoimmune gastritis (201). The destruction of parietal cells removes the source of both gastric acid and intrinsic factor, resulting in both gastric achlorhydria and pernicious anemia, respectively. The loss of intrinsic factor markedly reduces the efficiency of vitamin B12 absorption from food, which eventually leads to physiologically significant vitamin B12 deficiency. However, in the absence of any dietary cobalamin absorption, physiologic deficiency may not develop for 2 to 5 years because the liver stores about 3 mg of the vitamin.

Vitamin B12 deficiency as a manifestation of pernicious anemia may occur as part of an autoimmune polyglandular syndrome, frequently in association with type 1 diabetes mellitus, Hashimoto thyroiditis or hypothyroidism, and vitiligo (25; 194; 205; 178; 164; 217; 89).

Other gastrointestinal disorders. Besides pernicious anemia, various other iatrogenic conditions or naturally acquired gastrointestinal disorders can cause vitamin B12 deficiency.

Food-cobalamin malabsorption. A common cause of low vitamin B12 levels (but not necessarily of symptomatic deficiency) is the condition known as “food-cobalamin malabsorption,” in which vitamin B12 in food is absorbed poorly, but the crystalline vitamin B12 in vitamin pills is well absorbed (54; 38). Food-cobalamin malabsorption is associated with type B atrophic gastritis, a common condition that is associated with Helicobacter pylori infection. If gastric production of acid is reduced without concomitant loss of intrinsic factor (eg, as a result of H. pylori infection or medications), cobalamin absorption from food may be impaired (because the lack of the normal acidic environment of the stomach impedes the release of cobalamin from dietary proteins), but unbound cobalamin (eg, in supplemental vitamin preparations) will still be absorbed normally.

Bariatric surgery. Bariatric surgery may provide an anatomic and physiologic reason for vitamin B12 deficiency. Both purely restrictive (eg, banding) and malabsorptive (eg, Roux-en-Y bypass) procedures increase the risk of vitamin B12 deficiency, although the malabsorptive procedures are more likely to do so (65). A deficiency in vitamin B12 is the most common nutritional deficiency in patients who have had gastric bypass surgery (87), but deficiencies of folate, pyridoxine, thiamine, vitamin D, copper, zinc, iron, and calcium may also occur (160; 125). Without supplementation, 30% of patients with Roux-en-Y gastric bypass develop vitamin B12 deficiency (128). Even with supplementation (with good adherence to prescribed supplements), a significant proportion of men (10%) and women (17%) develop vitamin B12 deficiency (125).

Gastrectomy. Gastrectomy for any reason (eg, gastric cancer) increases the risk of deficiency because parietal cells, the source of intrinsic factor, are removed (12). In a meta-analysis of 14 studies of gastrectomy for gastric cancer, including collectively 2627 subjects, the prevalence of vitamin B12 deficiency after was 49% (20).

Pancreatic insufficiency. Patients with pancreatic insufficiency may have reduced cobalamin absorption (because pancreatic enzymes normally assist with the displacement of salivary haptocorrin binding protein by intrinsic factor), although such patients rarely become cobalamin deficient.

Bacterial overgrowth syndrome. Bacterial overgrowth syndrome is a disorder in which poor intestinal motility allows certain intestinal bacteria to grow excessively, causing diarrhea and malabsorption. Bacterial overgrowth syndrome may cause cobalamin deficiency because of competition for cobalamin in the intestine before the "cobalamin-intrinsic factor" complex reaches the terminal ileum.

Fish tapeworm infection. Fish tapeworm infection may cause cobalamin deficiency because of competition for cobalamin in the intestine before the "cobalamin-intrinsic factor" complex reaches the terminal ileum. This process served as a plot point (albeit markedly dramatized) for an episode titled "Insensitive" of the TV show House that aired on February 13, 2007.

Diphyllobothrium latum, a species of fish tapeworm, is the largest tapeworm that can infect people, reaching lengths of up to 30 feet long; because the tapeworm absorbs approximately 80% of dietary vitamin B12, prolonged infection causes vitamin B12 deficiency and megaloblastic anemia in about 40% of cases.

Diphyllobothrium latum spends a portion of its life cycle in crustaceans and fish. An adult tapeworm in a human intestine releases unembryonated eggs in feces, where they can be identified on microscopic analysis. In water, this develops into an embryonated egg, from which a coracidium hatches. Coracidia are ingested by crustaceans, the first intermediate host, and then develop into procercoid larvae in the body cavities of the crustaceans. When infected crustaceans are ingested by fish, the procercoid larvae are released, and the last larval stage, a plerocercoid, develops in the muscle of the fish. When infected small fish are eaten by larger predator fish, the plerocercoid invades the tissue of the larger fish. The plerocercoid is the infective stage for man and other definitive hosts, including many fish-eating mammals and birds. When someone eats raw or inadequately cooked fish, usually from the Northern Hemisphere (although cases have also been reported in Uganda and Chile), the scolex of the plerocercoid attaches to the human intestine. The adult tapeworm develops from this. Diagnosis is made by identification of eggs or segments of the tapeworm (ie, proglottids) in a stool sample with a microscope. Adequately freezing or cooking fish will kill the parasite.

Basic life cycle of the tapeworm, Diphyllobothrium latum

The basic life cycle of the tapeworm, Diphyllobothrium latum. This diagram depicts the various stages in the life cycle of the tapeworm and the cause of the disease, diphyllobothriasis. (Source: Centers for Disease Control and Pre...
Detailed life cycle of the tapeworm, Diphyllobothrium latum

This detailed diagram depicts the various stages in the life cycle of the tapeworm, Diphyllobothrium latum. (Source: Centers for Disease Control and Prevention. Public domain.)
Diphyllobothrium latum tapeworm egg

Under a magnification of 128X, this photomicrograph revealed the presence of a Diphyllobothrium latum tapeworm egg, which is oval or ellipsoidal, and ranges in size from 55 μm to 75 μm X 40 μm to 50 μm. The eggs are passed unembry...
Embryonated Diphyllobothrium latum egg

The appearance of an embryonated Diphyllobothrium latum egg. (Photograph by Stefan Walkowski 2011. Creative Commons Attribution-Share Alike 4.0 International License.)
Diphyllobothrium latum scolex

Under a magnification of 40X, this photomicrograph shows the appearance of a Diphyllobothrium latum scolex (the portion that attaches to a human intestine). (Photograph by 커뷰 (Kervu) 2014. Courtesy of Wikimedia Commons. Creativ...
Proglottids (segments) of the parasitic tapeworm, Diphyllobothrium latum

This photomicrograph shows the appearance and ultrastructural details exhibited by a number of gravid proglottids of the parasitic tapeworm, Diphyllobothrium latum. (Photograph by Dr. Mae Melvin 1979. Source: Centers for Disease C...

Pathology of the distal ileum. Any pathology of the distal ileum, where vitamin B12 is normally absorbed, may impair absorption of the intrinsic factor-cobalamin complex. Thus, cobalamin deficiency has been reported with regional enteritis, Whipple disease, ileal tuberculosis, tropical sprue, and surgical resection of the distal ileum, among other conditions. Although inflammation of the terminal ileum is common in Crohn disease and ulcerative colitis, some studies report that vitamin B12 deficiency is uncommon in these populations (22), whereas others report rates of vitamin B12 deficiency as high as 14% among patients with Crohn disease and 18% among patients with intestinal Behcet disease (an intestinal invasion of Behcet disease with chronic relapsing multisystem vasculitis disorder) (155).

Dietary cobalamin deficiency. Because no vegetable product is a reliable source of biologically active cobalamin, vegan diets can lead to cobalamin deficiency. Compared with patients with pernicious anemia, strict vegetarians (who produce intrinsic factor normally) retain more cobalamin from the enterohepatic circulation and, therefore, may take much longer (as long as 10 to 20 years) to become symptomatic from cobalamin deficiency. Despite this, cobalamin deficiency is common in vegans, occurring in up to half of such individuals who do not receive supplementation with vitamin B12 (103; 76; 66; 157).

Because the breast milk of mothers who are on predominantly vegetarian diets may be deficient in vitamin B12, especially in resource-poor countries, exclusive breastfeeding can result in B12 deficiency in the infant (91; 120; 122). This is a major causative factor to the high rate of vitamin B12 deficiency among infants and toddlers in India (93; 91). Infantile deficiency of vitamin B12 can affect neurodevelopmental outcome and cause spells, tremor, or irritability. Infantile B12 deficiency is characterized by developmental delay, sparse hair, hyperpigmentation, and tremors (105). Curiously, when treated with injectable B12, the affected babies can develop a peculiar transient "batwing dystonia" that may represent a "nutritional recovery" movement disorder (105).

Lacto-vegetarians are also at increased risk of vitamin B12 deficiency (113). A lacto-vegetarian (sometimes referred to as a "lactarian") diet is a diet that requires abstinence from the consumption of meat and eggs while allowing consumption of dairy products.

Rarely, individuals with psychiatric conditions, including autism spectrum disorder, have prolonged histories of selective eating, sufficient to impair vitamin B12 absorption over periods of at least 7 to 10 years (176).

Inborn errors of cobalamin metabolism. Several inherited conditions can cause actual or functional vitamin B12 deficiency. Two inherited disorders cause hereditary cobalamin deficiency: the Imerslund-Gräsbeck syndrome and congenital pernicious anemia (intrinsic factor deficiency).

Imerslund-Gräsbeck syndrome. The Imerslund-Gräsbeck syndrome is a rare autosomal recessive condition characterized by both a specific congenital deficiency in cobalamin absorption and proteinuria (198). The syndrome can be caused by mutations in either of the two proteins, cubulin and amnion-associated transmembrane protein (amnionless), which together form the receptor complex called "cubam," needed for cobalamin absorption from the ileum. Cubilin is the intestinal receptor for the endocytosis of the "cobalamin-intrinsic factor" complex, whereas amnionless is a transmembrane protein. Cubilin is coded by the CUBN gene on chromosome 10p13, and amnionless is coded by the AMN gene on chromosome 10q32.32. The "cubam" complex also forms a protein reabsorption complex in the proximal renal tubule.

Congenital pernicious anemia (intrinsic factor deficiency). Intrinsic factor deficiency, or "congenital pernicious anemia," is a rare autosomal recessive disorder characterized by the lack of gastric intrinsic factor in the presence of normal gastric acid secretion and mucosal cytology and in the absence of intrinsic factor antibodies found in the acquired form of pernicious anemia. Hereditary intrinsic factor deficiency is caused by homozygous or compound heterozygous mutation of the CBLIF gene on chromosome 11q12.1 (135; 197; 198).

Congenital transcobalamin II deficiency. Congenital transcobalamin II deficiency may cause megaloblastic anemia and neurologic abnormalities despite normal serum cobalamin levels. Transcobalamin II deficiency is an autosomal recessive disorder due to homozygous or compound heterozygous mutations in the TCN2 gene on chromosome 22q12.2. The clinical onset of transcobalamin II deficiency is in early infancy. The disorder is characterized by failure to thrive, megaloblastic anemia, pancytopenia, methylmalonic aciduria, recurrent infections, and vomiting and diarrhea. Treatment with cobalamin results in clinical improvement, but if left untreated the disorder may result in intellectual disability and neurologic abnormalities.

Cobalamin defects or diseases A-H. Various inherited defects in the synthesis of the biologically active forms of vitamin B12 (ie, adenosylcobalamin and methylcobalamin) from ingested cobalamin substrate are referred to as cobalamin defects or diseases A-H; these usually present in infancy, although neurologic and psychiatric presentations of cobalamin C defect have been described in adolescents and adults (174; 33; 227; 03; 92). Cobalamin defects A, B, and H are characterized by isolated increased levels of methylmalonic acid in the blood and urine (174); most of these patients present in infancy with recurrent episodes of ketoacidosis without megaloblastic anemia. Cobalamin defects E and G are characterized by hyperhomocysteinemia and hypomethioninemia without methylmalonic aciduria (174); most patients with these diseases present in the first months of life with megaloblastic anemia, poor feeding, and, if not promptly diagnosed, various neurologic deficits, such as abnormal muscle tone and seizures. Cobalamin defects C, D, and F are due to defective synthesis of both methylcobalamin (resulting in hyperhomocysteinemia and hypomethioninemia) and adenosylcobalamin (resulting in methylmalonic aciduria) (174); most of these patients present in the neonatal period with feeding difficulties, failure to thrive, neurologic deterioration, megaloblastic anemia, variable renal and liver failure, cardiomyopathy, pneumonia, and retinopathy.

The metabolic pathways involved in remethylation disorders are complex (79).

Metabolic pathways involved in remethylation disorders

Legend: AdoCbl, adenosyl-Cbl; AdoHcy, adenosylhomocysteine; AdoMet, adenosylmethionine; BHMT, betaine homocysteine methyltransferase; cbl C-G, cobalamin C-G; CBS, cystathionine-beta-synthase; CH2-THF, 5,10-methylenetetrahydrofo...

In addition, the age of onset is quite wide, even if most cases have onset in infancy. The clinical presentations vary by age (see Table 1) (79).

Table 1. Age-Related Clinical Presentations of Remethylation Disorders

Neonates (0 to 28 days)
	Encephalopathy
		Lethargy, apnea Feeding difficulties Muscular hypotonia Seizures
	Nystagmus Anemia, thrombocytopenia or pancytopenia, megaloblastosis Hemolytic uremic syndrome Cardiomyopathy Hydrocephalus Pulmonary hypertension
Infants (1 to 12 months)
	Growth failure or poor weight gain Acute progressive encephalopathy or apnea Chronic encephalopathy
		Muscular hypotonia Developmental disability or regression Seizures Recurrent acute behavioral changes or lethargy
	Visual inattention or nystagmus Anemia, thrombocytopenia or pancytopenia, megaloblastosis Hemolytic uremic syndrome Pulmonary hypertension
Children (1 to 12 years)
	Chronic encephalopathy
		Muscular hypotonia or spasticity Developmental disability, regression, or dementia Seizures Neuropsychiatric disturbance or personality changes Intermittent acute behavioral changes or lethargy
	Acute progressive encephalopathy or apnea Subacute degeneration of the cord
		Paresthesia Incontinence Ataxia or spasticity Progressive limb weakness (legs> arms)
	Hemolytic uremic syndrome Thromboembolic events
		Recurrent venous thrombosis Pulmonary thromboembolism Cerebrovascular events
	Pulmonary hypertension
Adolescents and adults (older than 12 years)
	Chronic encephalopathy
		Developmental disability, regression, or dementia Neuropsychiatric disturbance Personality changes Intermittent acute behavioral changes or lethargy
	Acute progressive encephalopathy Subacute degeneration of the spinal cord
		Paresthesia Incontinence Ataxia or spasticity
	Progressive limb weakness (legs> arms) Thromboembolic events
		Recurrent venous thrombosis Pulmonary thromboembolism Cerebrovascular events
	Pulmonary hypertension
From: (79)

Furthermore, multiple conditions mimic intracellular remethylation disorders, complicating the differential diagnosis of inborn errors of metabolism presenting with hyperhomocysteinemia (see Tables 2 and 3) (79).

Table 2. Conditions That Mimic Intracellular Disorders of Remethylation

Affecting cobalamin availability
	Nutritional inadequacy (maternal vitamin B12 deficiency or vegan diet) Intestinal malabsorption (eg, genetic disorders such as Imerslund-Graesbeck syndrome gastric intrinsic factor deficiency; autoimmune or parasitic disease; short gut syndrome) Disturbed binding and cellular uptake (eg, TC deficiency) Disturbance of intracellular metabolism (nitrous oxide)
Affecting folate availability
	Nutritional inadequacy (maternal deficiency or dietary inadequacy) Intestinal malabsorption (acquired or genetic) Disturbed binding and cellular uptake of folate (autoimmune or genetic) Disturbance of intracellular metabolism (antifolate drugs, MTHFD1 deficiency)
Other diseases with a combination of hematological and neurologic symptoms
	Severe iron deficiency Infectious diseases (eg, CMV, EBV, HHV6, HPVB19, or HIV1) Leukemia or myeloproliferative disorders Myelodysplastic syndromes Disorders affecting the mitochondrial respiratory chain (eg, Pearson syndrome) UMP synthase deficiency (orotic aciduria) Thiamine transporter (SLC19A2) defect Branched-chain organic acidemia such as methylmalonic or propionic acidemia Lysinuric protein intolerance
From: (79)

Table 3. Differential Diagnosis of Inborn Errors of Metabolism Presenting with Hyperhomocysteinemia

	Macrocytosis or macrocytic anemia	MMA	Met	Total vitamin B12	Folate
cblC
cblD-MMA/HC	+ or −	↗	↘↘ to nl	nl	nl
cblF/cblJ	+	↗	↘↘ to nl	nl	nl
cblE/G	+	nl	↘↘ to nl	nl	nl
cblD-HC	+ or −	nl	↘↘ to nl	nl	nl
MTHFR	–	nl	↘↘ to nl	nl	nl or ↘
Vitamin B12 deficiency or malabsorption	+	↗	↘ to nl	↘↘	nl
Folate deficiency or malabsorption	+	nl	↘ to nl	nl	↘↘
HCFC1 (cblX)	+ or −	↗ or nl	↘↘ to nl	nl	nl
CBS deficiency	–	nl	nl-↗	nl	nl
TC deficiency	+	↗	↘↘ to nl	nl (↘)	nl
MTHFD1 deficiency*	+	nl	↘↘ to nl	nl	Nl
*Hyperhomocysteinemia present in some patients, normal (nl) tHcy levels in others From: (79)

Huemer and colleagues have developed a diagnostic and management pathway for patients with a suspected remethylation disorder and have provided a comparison of the various cobalamin defects associated with hyperhomocysteinemia, the respective enzymatic/incorporations tests available, and the genes involved in these diseases (see Table 4) (79).

Diagnostic pathway and management of the patient with a suspected remethylation disorder

Legend: Met, methionine; MMA, methylmalonic acid; MTHFD1, methylenetetrahydrofolate dehydrogenase 1; MTHFR, methylenetetrahydrofolate reductase; N, normal; OHCbl, hydroxotranscobalamin; TC, transcobalamin VitB12, tHcy, total ho...

Table 4. Representation of the Cobalamin Defects Associated with Hyperhomocysteinaemia, the Respective Enzymatic/Incorporations Tests Available and the Genes Involved in these Diseases

	cblC	cblD-MMA/HC	cblF	cblJ	cblD-HC	cblE	cblG	MTHFR
Direct enzyme assay (tissues)	no	no	no	no	no	yes	yes	yes
						fib/leuc/amn	fib/leuc/amn	fib/leuc/amn
Indirect enzyme assays
Propionate incorporation	↘	↘	↘	↘	nl	nl	nl	nl
MTHF incorporation	↘	↘	↘	↘	↘	↘	↘	nl
Formate incorporation into serine	↘	↘	↘	↘	↘	↘	↘	nl or ↗
Formate incorporation into methionine	↘	↘	↘	↘	↘	↘	↘	↘
AdoCbl biosynthesis	↘	↘	↘	↘	nl	nl	nl	nl
MeCbl biosynthesis	↘	↘	↘	↘	↘	↘	↘	↘
Gene	*MMACHC*	MMADHC	LMBRD1	ABCD4	MMADHC	MTRR	MTR	MTHFR
Chromosome location	1p34.1	2q23.2	6q13	14q24.3	2q23.2	5p15.31	1q43	1p36.22
Mode of inheritance	AR	AR	AR	AR	AR	AR	AR	AR
OMIM	609831	611935	612625	603214	611935	602568	156570	607093
fib=fibroblasts, leuc=leukocytes, amn=amniocytes, AR=autosomal recessive, nl=normal From: (79)

Despite treatment, many complications may occur from these disorders (see Table 5).

Table 5. Main Complications According to System in Remethylation Disorders

Growth and physical features	Prenatal growth retardation and postnatal failure to thrive Dysmorphic facial features
CNS	Microcephaly Hydrocephalus Developmental delay and/or regression; cognitive impairment ranging from executive dysfunction to severe mental retardation Neuropsychiatric disturbances, social withdrawal, personality changes, dementia Progressive encephalopathy Seizures Subacute combined degeneration of the spinal cord Peripheral neuropathy Leukoencephalopathy Cortical atrophy
Eye	Nystagmus Maculopathy Progressive pigmentary retinopathy Optic atrophy Visual impairment/blindness
Blood	(Macrocytic) anaemia Thrombocytopenia and/or neutropenia
Vascular	Stroke Recurrent venous thrombosis Cor pulmonale or subclinical pulmonary thrombosis
Renal	Haemolytic-uremic syndrome Glomerulopathy
Heart	Congenital heart defects Left ventricular non-compaction Dilated cardiomyopathy Pulmonary hypertension
From: (79)

Huemer and colleagues have also provided guidelines for treatment of these disorders (see Table 6) (79).

Table 6. Recommended Treatment of Remethylation Disorders

	Drugs with proven clinical effect	Treatments without proven clinical effect	To be avoided
Cobalamin related remethylation disorders	OHCbl parenteral	Folate/folinic acid	Nitrous oxide
	Betaine	L-Carnitine	Protein restriction
		Methionine*
MTHFR deficiency	Betaine	Folinic acid/5-Methylfolate*	Nitrous oxide
		L-Carnitine	Folic acid
		Methionine*	Protein restriction
*Has been applied with clinical benefit in single cases From: (79)

Treatment should be initiated with parenteral hydroxocobalamin without delay in any suspected remethylation disorder because it significantly improves survival and incidence of severe complications (79).

Cobalamin C defect or deficiency. Cobalamin C defect or deficiency is the most common inborn error of cobalamin metabolism, with an estimated prevalence of 1:200,000 births (03). Cobalamin C defect causes the accumulation of methylmalonic acid and homocysteine and decreased methionine synthesis. The gene responsible for the cobalamin C defect is the MMACHC, located on chromosome 1p34.1 (116). Cobalamin C defect causes impaired conversion of dietary vitamin B12 into its two metabolically active forms, methylcobalamin and adenosylcobalamin (132). The gene product catalyzes the reductive decyanation of cyanocobalamin. Adult cases are usually compound heterozygous carriers of a truncating and a nontruncating variant in the MMACHC gene (92).

Although the age of onset varies from prenatal to adult, most patients present in infancy. In infancy, cases have combined methylmalonic aciduria and homocystinuria. Early-onset cases of cobalamin C defect present with multisystem disease within the first year, with severe neurologic (eg, lethargy, hypotonia, microcephaly, seizures, stroke, neurodevelopmental delay), ocular (eg, rapidly progressing maculopathy with severe photoreceptor and ganglion cell loss), hematological, renal (eg, atypical hemolytic-uremic syndrome, renal arteriolar and glomerular thrombotic microangiopathy), gastrointestinal (eg, vomiting, diarrhea, feeding difficulties), cardiac, and pulmonary manifestations (eg, apneic episodes) (116; 32; 115; 33; 227; 90; 219). Neonatal screening and early treatment can potentially improve the prognosis at least somewhat (227); but even with neonatal screening, outcomes are poor despite early initiation of therapy and regardless of the dietary strategy used (02).

Despite the predominance of early-onset cases, more than 30 cases of adolescent-onset (12 to 17 years) and more than 30 cases of adult-onset (18 years or older) cobalamin C defect have been reported (03). Late-onset cases generally have a milder clinical phenotype with acute or slowly progressive neurologic symptoms and behavioral disturbances (03).

Young woman with vitamin B12 deficiency neurologic syndrome due to late-onset cobalamin C deficiency (serial MRI studies of brain and spinal cord)

At the time of diagnosis, brain MRI showed diffuse white matter lesions in both hemispheres (T2) with diffusion restriction (A and B), and spinal MRI revealed subacute combined degeneration of the cord (C). After 42 months of t...

Adolescent cases may have autism spectrum disorder, mental retardation, rapidly progressing maculopathy with severe photoreceptor and ganglion cell loss, and movement disorders (32; 227; 143). Rapidly progressing maculopathy with severe photoreceptor and ganglion cell loss, renal thrombotic microangiopathy, hemolytic uremic syndrome, pulmonary hypertension, and pulmonary thrombotic events have also been described in adult-onset cobalamin C defect (32; 03; 92).

Adult patients with cobalamin C defect pose a diagnostic challenge because they typically present with normal to high-normal serum vitamin B12 concentrations without macrocytic anemia (03; 92). Cobalamin C defect should be considered in the differential diagnosis in adult patients with atypical hemolytic uremic syndromes, slow unexplained decline in renal function, idiopathic neuropathies, spinal cord degenerations, ataxias, unexplained or recurrent thrombosis, visual field defects, maculopathy, and optic disc atrophy (92). Plasma homocysteine measurement should be obtained when the disease is suspected (79; 92). To further aid diagnosis, genes belonging to the intracellular cobalamin pathway should be routinely included in gene panels for atypical hemolytic uremic syndrome and chronic kidney disorders.

Treatment should be initiated with parenteral hydroxocobalamin without delay with cobalamin C defect, as in any suspected remethylation disorder, because it significantly improves survival and incidence of severe complications (79). In adult cases, treatment with intramuscular hydroxycobalamin was effective in reversing symptoms (92). Earlier recommendations advocated treatment of the cobalamin C defect with a combined approach that utilizes vitamin B12 plus betaine to provide a substrate for the conversion of homocysteine into methionine through betaine-homocysteine methyltransferase, and folic acid to enhance the remethylation pathway (132). It is unclear if these additional measures change clinical outcomes. No proven efficacy has been demonstrated for carnitine and dietary protein restriction (132).

Despite these measures, the long-term outcomes are unsatisfactory, especially in cases with early onset, with frequent progression of neurologic and ocular impairment (132; 33).

Medication-induced cobalamin deficiency. Medications are not an uncommon etiology of vitamin B12 deficiency.

Nitrous oxide. Nitrous oxide irreversibly oxidizes the cobalt in cobalamin, which effectively inactivates vitamin B12.

Alterations in biochemical pathways induced by nitrous oxide

Nitrous oxide inactivates vitamin B12 by oxidation of the cobalt atom, leading to functional defects in vitamin B12 as a cofactor for the catabolism of homocysteine and methylmalonic acid. Thus, the circulating concentrations o...

Thus, a functional deficiency of cobalamin can be created by the inhalation of nitrous oxide, a common anesthetic agent and recreational drug (48; 114). Nitrous oxide abusers can have non-B12-related psychiatric problems, as might be expected for substance abusers in general (156).

Proton pump inhibitors or H2-receptor blocking agents. Proton pump inhibitors and H2-receptor-blocking agents have been implicated as causes or contributors to vitamin B12 deficiency because they can produce iatrogenic gastric achlorhydria (88). A decrease in serum cobalamin levels has been demonstrated after 3 to 4 years of omeprazole therapy.

Metformin. Diabetics on metformin are also at risk for vitamin B12 deficiency because the drug impairs vitamin B12 absorption (08; 26; 78; 97). The mechanism of this effect has been debated (200; 09), and the relationship between metformin exposure and vitamin B12 deficiency remains somewhat ill-defined (154; 172; 224). Several randomized, placebo-controlled trials indicate that metformin therapy leads to a progressive decline in vitamin B12 levels and can cause physiologically significant deficiency (121). Metformin-related vitamin B12 deficiency may cause or accelerate distal symmetrical and autonomic neuropathy in the patient with diabetes (26). Patients randomized to metformin therapy in the Diabetes Prevention Program Outcome Study were more likely to show vitamin B12 deficiency or borderline low vitamin B12 levels (14). Populations already vulnerable to vitamin B12 deficiency, such as the institutionalized elderly, may be at especially heightened risk of deficiency in the setting of metformin use (218). Although routine B12 supplementation in patients on metformin therapy is not currently the standard of care (222), it is reasonable to monitor vitamin B12 levels in patients on metformin, particularly for individuals on long-term metformin (80; 81) or high-dose metformin (≥1500 mg/day) (64; 81), both of which are risk factors for metformin-associated vitamin B12 deficiency (64; 80; 81). Certainly, development of peripheral polyneuropathy in a diabetic patient on metformin should not be assumed to be due to diabetes alone without checking a vitamin B12 level.

A previously unappreciated mechanism may explain the relationship between metformin use and vitamin B12 deficiency. Apparently, metformin acts directly on gut bacteria to increase their vitamin B12 uptake, leading to increasing competition for available dietary vitamin B12 and ultimately to human vitamin B12 deficiency (44). Bacteroides ovatus abundance was negatively correlated with serum levels of vitamin B12 in subjects with type 2 diabetes who received metformin treatment. Bacteroides ovatus accumulates cobalamin due to BtuB upregulation; BtuB, a bacterial outer membrane vitamin B12 receptor/transporter, transports vitamin B12 across the outer membrane of gram-negative bacteria. Upregulation of this transporter effectively sequesters dietary vitamin B12 so it cannot be absorbed from the gut. The metabolic effects of metformin vary somewhat across gram-negative bacteria: (1) in E coli metformin inhibits respiratory chain complex I, impairing the function of the inner membrane vitamin B12 transporter (BtuCD), so vitamin B12 entry is blocked at the inner membrane, causing vitamin B12 to accumulate in the periplasm; (2) in contrast, in B ovatus metformin upregulates respiratory chain complex V so that vitamin B12 can be transported across inner membrane to the bacterial cytoplasm (44).

Metabolic effects of metformin on gut bacteria

Metabolic effects of metformin on gut bacteria to increase their vitamin B12 uptake, leading to increasing competition for available dietary vitamin B12 and ultimately to human vitamin B12 deficiency. In E. coli metformin inhib...

In an experimental test of the effectiveness of this mechanism, B ovatus accelerated metformin-induced vitamin B12 deficiency in mice fed a high-fat diet.

Levodopa. Conflicting evidence links chronic levodopa therapy in patients with Parkinson disease to an increased risk of symptomatic vitamin B12 deficiency, perhaps because carbidopa metabolism through the catechol-O-methyl transferase pathway may deplete vitamin B12-dependent cofactors (162; 41; 138). Patients receiving continuous enteral levodopa infusions may be particularly at risk (138; 134). Checking vitamin B12 levels may be worthwhile prior to instituting levodopa therapy and also periodically in patients under chronic treatment.

Epidemiology

	• The elderly are at increased risk of cobalamin deficiency, with rates of laboratory-diagnosed deficiency near 15% in some studies.
	• Both vegans and vegetarians have increased rates of vitamin B12 deficiency.
	• Other groups at high risk include those with (1) HIV infection and AIDS; (2) malnutrition; (3) intestinal parasitism; and (4) Crohn disease, particularly those who have had an ileal resection.

The elderly are at increased risk of cobalamin deficiency, with rates of laboratory-diagnosed deficiency near 15% in some studies.

Both vegans (those whose diets allow no animal products) and vegetarians (diets that can include some dairy or eggs but no meat) have high rates of functional vitamin B12 deficiency (76; 66; 157; 171). Of particular concern are the breastfed infants of vegetarian or vegan mothers and children on vegetarian or vegan diets (40).

Other groups at high risk include those with HIV infection and AIDS as well as certain populations outside the United States where malnutrition and intestinal parasitism may play a role (11). Persons with Crohn disease, particularly those who have had an ileal resection, are at increased risk of vitamin B12 deficiency (29).

Vitamin B12 deficiency and dementia. Many epidemiological investigations have reported an association between lower levels of vitamin B12 or folate (or elevated blood homocysteine and methylmalonic acid, which are metabolic indicators of vitamin B12 deficiency) and Alzheimer disease or other forms of cognitive impairment (45; 213; 191; 94; 102; 107). A community-based study of elderly persons similarly showed that serum indices of relative vitamin B12 levels were associated with increased risk of progressive brain atrophy over 5 years (208). Another study of elderly community-dwelling individuals found that low vitamin B12 levels were associated with poorer memory (140). In contrast, a Danish cohort study showed no association between low plasma vitamin B12 levels and dementia (13).

Studies in rodent models of Alzheimer disease demonstrate that both B-vitamin deficiency and hyperhomocysteinemia can increase levels of the amyloid-forming peptides A-beta 1-40 and A-beta 1-42, increase levels of beta-amyloid plaque, and cause cognitive impairment (152; 228; 229).

Despite the suggestive epidemiological and experimental data, no prospective trial has demonstrated that supplementation of the diet with vitamin B12 or folate can prevent or delay the onset of Alzheimer disease or other dementia. The cognitive performance of patients with mild or moderate B12 deficiency and dementia usually does not improve with vitamin B12 supplementation (39; 47; 108; 192; 59; 21). The VITALS trial randomly assigned 409 patients with clinically diagnosed Alzheimer disease (MMSE scores between 14 and 26) and normal vitamin B12, folate, and total homocysteine levels to daily B vitamin supplementation (B12 1 mg, B6 25 mg, folate 5 mg) or placebo, and followed the patients for 18 months (04). No effect on the rate of decline of cognitive function was observed.

Modest and inconclusive beneficial effects of vitamin B12 supplementation were observed in two trials. In an Australian study of the effect of vitamin B12, folate, and other randomized interventions on cognitive function in a group of subjects at increased risk for depression, an improvement in some memory tests was observed in those randomized to vitamin B12 and folate supplementation (211). A British group has found that vitamin B12 and folate supplementation reduced the rate of brain atrophy in persons with mild cognitive impairment, and this effect was particularly pronounced in those subjects with higher levels of homocysteine at baseline (184; 55). The effect on tests of cognition was not reported in detail.

The discrepancy between, on the one hand, repeated findings of an association between indices of relative vitamin B12 deficiency and cognitive impairment and, on the other hand, the lack of substantial benefit in therapeutic trials of B vitamin supplementation is not understood. Most clinical trials have been of relatively short duration, so it is possible that more substantial benefits would be seen with more prolonged therapy (73).

B vitamins and cerebrovascular disease. Observational studies have found a direct relation between mild or moderately elevated serum homocysteine levels and the risk of both coronary artery disease and cerebrovascular thrombosis (206; 226; 167). Mild to moderate elevations in homocysteine may also be associated with increased risk for cranial artery dissections (63). Cobalamin deficiency, which elevates plasma homocysteine, might, thus, be a cause of otherwise unexplained ischemic stroke or cranial artery dissection (159; 215). Total homocysteine levels are inversely related to the levels of both folate and cobalamin consumed in the diet (182), but in countries where grain products are fortified with folate, vitamin B12 intake may be the major determinant of homocysteine levels (72). Thus, cobalamin deficiency might increase the risk of cerebral and myocardial infarction by increasing serum homocysteine levels.

In a retrospective cross-sectional study of 165 patients with thromboembolic and other cardiovascular manifestations identified among 1006 hospitalized patients, 165 patients (84%) had at least moderate hyperhomocysteinemia with levels greater than 30 μmol/L, 27% had levels greater than 50 μmol/L, and 3% had severe elevations greater than 100 μmol/L (117). Hyperhomocysteinemia was related to vitamin B12 or folate deficiency in 55%, mutations in one or more genes of one-carbon or vitamin B12 metabolisms in 11%, and severe renal failure in 15%. Hyperhomocysteinemia was the sole vascular risk identified in almost 9% of patients. Sixty percent received a vitamin supplement to treat hyperhomocysteinemia, with a significant decrease in median homocysteine levels. No recurrence of thromboembolic manifestations was observed after vitamin supplementation and antithrombotic treatment of patients who had hyperhomocysteinemia as an isolated risk factor after approximately 4 years of follow-up.

Conclusion. The high frequency of intermediate or severe hyperhomocysteinemia differs from the frequent moderate hyperhomocysteinemia reported in previous observational studies of patients with pre-existing cerebrovascular disease. Our study points out the importance of diagnosing and treating nutritional deficiencies and inherited disorders to reverse intermediate or severe hyperhomocysteinemia associated with cerebrovascular disease outcomes.

Despite these observational studies, the prospective, blinded, and placebo-controlled VISP, NORVIT, HOPE-2, WAFACS, VITATOPS, and SEARCH trials have all failed to show a significant benefit of high-dose B vitamin (including cobalamin) supplementation for preventing thrombotic vascular events or death (202; 31; 126; 07; 193; 207). These six large studies were similar in design. All examined the effect of combined folate and vitamin B12 supplementation (most with vitamin B6 or pyridoxine as well) on the rate of thrombotic vascular events in high-risk subjects. Subjects were recruited from patients with nondisabling cerebral infarction (VISP); myocardial infarction (NORVIT); cerebrovascular disease, peripheral vascular disease, or coronary disease or diabetes (HOPE-2); or female health professionals with known cardiovascular disease or vascular disease risk factors (WAFACS), recent stroke or transient ischemic attack (VITATOPS), or myocardial infarctions (SEARCH). Subjects were followed for 24 (VISP), 40 (NORVIT), 60 (HOPE-2), 88 (WAFACS), 41 (VITATOPS), or 80 months (SEARCH). No study demonstrated a significant reduction in the rate of coronary events or stroke. The dose of vitamin B12 used in the VISP and NORVIT trials and issues with the design of the VISP trial might have obscured a small but still meaningful benefit to vitamin B12 supplementation (186). A metaanalysis of patients from two large trials revealed that patients with normal kidney function may benefit from vitamin B12 supplementation for stroke prevention, whereas patients with impaired kidney function may not (187).

Differential diagnosis

Confusing conditions

The neurologic manifestations of vitamin B12 deficiency are not specific, and other causes of subacute to chronic neuropathy, myelopathy, or both will need consideration depending on the clinical scenario. A differential for the myelopathy would include various metabolic, toxic, immunologic, and infectious disorders, such as copper deficiency myelopathy (possibly precipitated by zinc toxicity), folate deficiency myelopathy, vitamin E deficiency myelopathy, nitrous oxide toxicity, HIV-related vacuolar myelopathy, HTLV-1 associated myelopathy, neurosyphilis, and possibly Lyme disease. Conditions with acute or episodic or relapsing-remitting courses are less likely to be confused with vitamin B12 deficiency myelopathy (eg, trauma, multiple sclerosis), as are myelopathies resulting from intramedullary lesions or extramedullary compression. In cases where peripheral neuropathy is the presenting feature, evaluation for common causes (eg, impaired glucose metabolism, hypothyroidism) is necessary, keeping in mind that autoimmune disorders can present with combinations of disorders (eg, pernicious anemia, autoimmune thyroid dysfunction, and type 1 diabetes).

The hematologic and gastrointestinal signs of vitamin B12 deficiency can be mimicked by folate deficiency (53; 165).

A deficiency of vitamin B12 transport in the blood may rarely cause subacute combined degeneration in the presence of normal serum vitamin B12 levels (169).

Although rare, copper deficiency may present with subacute combined degeneration (104; 84). Copper deficiency may follow bariatric surgery or zinc ingestion. Until recently, zinc was present in high quantities in dental adhesives (85). Toxic zinc exposures may occur with ingestion of coins (eg, in schizophrenics and children) and in certain occupational exposures (110).

Diagnostic workup

	• Although there is no well-accepted “gold standard” for confirming vitamin B12 deficiency, there are two somewhat complementary methods of assessing vitamin B12 status: (1) directly measuring vitamin B12 levels in the serum and (2) measuring levels of metabolites (fasting serum homocysteine and serum methylmalonic acid levels) that accumulate as a result of inadequate vitamin B12.
	• Many patients with neurologic signs of vitamin B12 deficiency do not have readily detectable hematological abnormalities.
	• Traditionally, evaluation of possible vitamin B12 deficiency begins with measurement of the serum cobalamin level, although neurologically significant deficiency may occur with low-"normal" serum levels.
	• In cases with borderline low serum cobalamin levels, measuring serum methylmalonic acid and fasting homocysteine levels may clarify whether these are truly low-normal values, or whether these instead indicate a physiologically significant functional vitamin B12 deficiency.
	• From a diagnostic standpoint, it is not sufficient to establish the presence of vitamin B12 deficiency; it is also necessary to determine why the cobalamin deficiency developed in the first place.
	• A laboratory-supported clinical diagnosis of cobalamin deficiency, with hematologic or neurologic changes implies the presence of long-standing gastrointestinal disease until proven otherwise.
	• Simply treating the cobalamin deficiency does not address the underlying problem that brought about the cobalamin deficiency.
	• Cobalamin deficiency should not be assumed to be due to pernicious anemia (ie, autoimmune destruction of parietal cells resulting in intrinsic factor deficiency) simply because that is the most common cause.
	• A diagnosis of pernicious anemia can be made by demonstration in the serum of either anti-intrinsic factor antibodies or antibodies to gastric parietal cells in the setting of symptomatic vitamin B12 deficiency. However, the absence of such antibodies does not exclude the diagnosis of pernicious anemia.
	• In the absence of confirmatory antibody studies establishing a diagnosis of pernicious anemia, gastroenterology consultation and other diagnostic tests (eg, endoscopy) may be necessary to determine the cause of cobalamin deficiency if a clear and sufficient explanation is not readily evident from the patient's history.

Although there is no well-accepted “gold standard” for confirming vitamin B12 deficiency, there are two somewhat complementary primary methods of assessing vitamin B12 status: (1) directly measuring vitamin B12 levels in the serum and (2) measuring levels of metabolites that accumulate as a result of inadequate vitamin B12. In addition, supportive testing addresses hematological abnormalities, but hematological abnormalities should not be considered an adequate screening test for vitamin B12 deficiency (vide infra). Ancillary testing may include neuroimaging and electrophysiological tests.

Once vitamin B12 deficiency is established, it is critical to identify the underlying cause of the deficiency. Appropriate evaluation for this purpose includes antibody tests for pernicious anemia, consideration of gastroenterology consultation, and possibly endoscopy.

Hematological abnormalities. Many patients with neurologic signs of vitamin B12 deficiency do not have readily detectable hematological abnormalities, such as megaloblastic anemia (also known as macrocytic anemia) or neutrophils with hypersegmented nuclei (119; 74; 163; 210). Although hypersegmented neutrophils (ie, neutrophils with five or more nuclear lobes) are most often associated with megaloblastic anemia (eg, folic acid or vitamin B12 deficiency, including pernicious anemia), they may also be seen in myelodysplastic syndromes, in patients receiving chemotherapy, or in long-term chronic infections. Even when present, hypersegmented neutrophils are easily missed on routine examination of the blood smear. Folate supplementation can normalize the hematologic abnormalities in vitamin B12 deficiency (thereby potentially obscuring or delaying diagnosis), but even patients who are not taking folate supplements may have no evident hematologic abnormalities despite symptomatic vitamin B12 deficiency. Therefore, clinicians need to recognize the neurologic symptoms and signs of vitamin B12 deficiency and specifically seek evidence for this diagnosis if it might explain a patient’s condition rather than waiting for hematologic evidence of vitamin B12 deficiency to turn up on a complete blood count ordered for that or other purposes.

Bone marrow aspirates may support the diagnosis of megaloblastic anemia, demonstrating erythroid hyperplasia and megaloblasts with sieve-like nuclear chromatin and megaloblasts with giant, abnormal-shaped stab forms (153).

Bone marrow aspirate in megaloblastic anemia with cutaneous hyperpigmentation (1)

Bone marrow aspirate smears demonstrating erythroid hyperplasia and megaloblasts with sieve-like nuclear chromatin (thick arrow). This is consistent with a diagnosis of megaloblastic anemia (May-Grünwald-Giemsa staining x400). ...
Bone marrow aspirate in megaloblastic anemia with cutaneous hyperpigmentation (2)

Bone marrow aspirate smears demonstrating erythroid hyperplasia and megaloblasts with giant, abnormal-shaped stab forms (thin arrow). This is consistent with a diagnosis of megaloblastic anemia (May-Grünwald-Giemsa staining x40...

Cobalamin levels. Traditionally, evaluation of possible vitamin B12 deficiency begins with measurement of the serum cobalamin level. Usual lower limits of normal are approximately 170 ng/L (111 pM/L) for the radioimmunoassay and 250 ng/L (184 pM/L) for the chemiluminescent assay. However, neurologically significant deficiency may occur with low-"normal" serum levels. In addition, serum vitamin B12 concentrations may vary with the concentrations of the binding proteins. Falsely increased values may be caused by myeloproliferative disorders or liver disease, whereas falsely low values can be seen with folate deficiency, pregnancy, multiple myeloma, and transcobalamin deficiencies. In some patients with myeloproliferative disorders or liver disease, increased levels of serum haptocorrins result in increases in the measured serum cobalamin level (without actually increasing the physiologically active holotranscobalamin fraction).

Diagnosis is further complicated by the fact that certain automated assays may indicate false normal, or even elevated, vitamin B12 levels in patients with high levels of anti-intrinsic factor antibodies, and such antibodies are found in 70% of patients with pernicious anemia (37; 223; 189).

Serum cobalamin levels do not strictly correlate with physiologic deficiency, in part because traditional assays measure total serum cobalamin, even though the fraction bound to transcobalamin II (holotranscobalamin II) is physiologically most important. Certain conditions, such as liver disease, can increase serum haptocorrin, thereby increasing total serum cobalamin, even with relatively low levels of cobalamin bound to transcobalamin II (185).

Holotranscobalamin II. Transcobalamin II transports cobalamin in plasma to receptors on cell membranes; only the fraction of cobalamin that is bound to transcobalamin II is biologically active. Although some investigators have advocated the measurement of serum holo-transcobalamin II as a theoretically better measure of active vitamin B12, its clinical superiority has not been established, and holo-transcobalamin II assays are technically difficult to perform (100; 146; 68; 204; 37).

Metabolites: methylmalonic acid and fasting homocysteine. In cases with borderline low serum cobalamin levels, measuring serum methylmalonic acid (MMA) and fasting homocysteine levels may clarify whether these are truly low-normal values or whether these instead indicate a physiologically significant functional vitamin B12 deficiency. In addition, if a patient’s clinical situation strongly suggests vitamin B12 deficiency (eg, based on characteristic neurologic abnormalities), MMA or fasting homocysteine levels should be determined, even if the lab reports a normal or even high vitamin B12 level. Testing of MMA has additional value in identifying patients with clinically relevant metabolic deficiency when vitamin B12 is below 304 pmol/L (412 pg/mL) (214).

MMA is somewhat more sensitive than fasting homocysteine as an indicator of cobalamin deficiency, but some vitamin B12 deficient patients have an isolated elevation of homocysteine (68). Defining the levels of MMA or homocysteine that are definitely pathologic is difficult. Traditionally, greater than three standard deviations above the mean is considered elevated, but levels less elevated than this will often decline in patients supplemented with cobalamin or folate, perhaps indicating a relative deficiency of these vitamins. The greater-than-3-standard-deviation cutoff for serum MMA is generally around 350 nM/L and for homocysteine is 15 µM/L (20 µM/L in patients over age 60 years). A practice guideline of the American Academy of Neurology recommends measuring MMA or fasting homocysteine levels in patients with unexplained distal symmetric polyneuropathy and low-"normal" vitamin B12 levels (57). A retrospective case series found that 10 of 23 patients with neuropathy, low-"normal' vitamin B12 levels, and elevated MMA levels improved with vitamin B12 supplementation (141).

Although methylmalonic acid is an important functional marker of vitamin B12 deficiency, vitamin B12 status is not the only determinant of MMA levels. Methylmalonic acid levels also relate to renal function, endogenous production of propionic acid, and the function of various genes (170). In fact, less than a quarter of the variation in MMA levels is explained by vitamin B12 levels, eGFR, age, and sex, indicating that a large part of the variation in MMA levels is attributable to other factors (eg, catabolism, dietary components, or gut microbial production). Correcting plasma MMA for eGFR can reclassify plasma MMA levels across decision limits for diagnosing B12 deficiency, particularly for patients with reduced kidney function (eg, grade 3 or worse chronic kidney disease) (145).

Higher MMA levels are associated with an increased risk for mortality, independent of vitamin B12 status and sex, but are more pronounced in individuals with impaired renal function (170).

Deficiency of vitamin B12 or folic acid can lead to increased homocysteine levels.

Ancillary studies. Several ancillary studies may help support the diagnosis and also serve as indicators of the severity of neurologic involvement.

Neuroimaging. MRI scans in patients with vitamin B12 deficiency may show nonspecific regional hyperintensities in the affected tracts or structures on T2-weighted images, but the sensitivity of MRI for detecting signs of vitamin B12 deficiency is low (83). Typically, these MRI abnormalities are found in the posterior columns, but abnormalities may also be found in the cerebral white matter and, rarely, in other locations, such as the globus pallidus (42; 111; 181). In a population-based cohort study, the burden of MRI T2 hyperintensities in the white matter correlated with biochemical indices of relative vitamin B12 deficiency, even when these indices were in the generally accepted normal range (50). In infants with vitamin B12 deficiency, MRI may show delayed myelination (69).

Electrophysiological studies. On electrophysiology studies, the characteristic abnormality of vitamin B12 deficiency in the peripheral nervous system motor is a length-dependent sensory axonopathy (61). Evidence of denervation is typically greater in sensory axons than in motor axons and is more severe distally than proximally. Conduction velocities are normal. Sensory evoked response studies may show prolonged L3-P27 intervals (indicating slowed conduction between the cauda equina and the somatosensory cortex of the brain). Visual-evoked responses may be normal or may show abnormalities in patients with subacute combined degeneration, even in the absence of visual symptoms (75; 61).

Megaloblastic changes in the bone marrow are usually seen in vitamin B12 deficiency, even in the absence of abnormalities in the indices of circulating erythrocytes.

Ascertaining the cause of cobalamin deficiency. From a diagnostic standpoint, it is not sufficient to establish the presence of vitamin B12 deficiency; it is also necessary to determine why the cobalamin deficiency developed in the first place. A laboratory-supported clinical diagnosis of cobalamin deficiency, with hematologic or neurologic changes, implies the presence of long-standing gastrointestinal disease until proven otherwise. Simply treating the cobalamin deficiency does not address the underlying problem that brought about the cobalamin deficiency.

Cobalamin deficiency should not be assumed to be due to pernicious anemia (ie, autoimmune destruction of parietal cells resulting in intrinsic factor deficiency) simply because that is the most common cause. Vitamin B12 deficiency may be the first sign of otherwise overlooked abnormalities of the gastrointestinal system. At an elementary level, it is important to obtain a careful dietary history, review medications thoroughly to identify any that may interfere with cobalamin absorption or metabolism, and obtain a thorough review of systems and past medical history to identify potential causes of cobalamin deficiency.

Cobalamin absorption testing (Schilling test). The Schilling test, which was developed in 1953, relied on radiolabeled cobalamin to track defects in absorption. This test was previously used to investigate and clarify the cause of cobalamin deficiency, but unfortunately, this test is currently not available in the United States (35). There were two parts to the test: (1) cobalamin malabsorption was identified by poor urinary excretion of an oral dose of cobalamin; (2) gastric pathologies were identified by demonstrating a significant increment in urinary excretion of an oral dose of cobalamin when administered in combination with an external source of intrinsic factor, whereas the absence of a significant increment under these circumstances indicated an intestinal pathology.

Unfortunately, the test proved to be too complicated and unwieldly for many patients and their clinicians as it required "an overnight fast, ingestion of (modestly) radioactive cobalamin, a 24-hour collection of urine, a cobalamin injection, two trips to the laboratory, and, if the result [was] abnormal, repetition of the entire procedure with a dose of [intrinsic factor]" (35). In addition, it required normal renal function and complete urine collection.

Antibody tests for pernicious anemia. A diagnosis of pernicious anemia can be made by demonstration in the serum of either anti-intrinsic factor antibodies or antibodies to gastric parietal cells in the setting of symptomatic vitamin B12 deficiency (35); these antibodies are specific but not very sensitive. Therefore, the absence of such antibodies does not exclude the diagnosis of pernicious anemia.

Gastric parietal cell antibodies can be detected in roughly 90% of those with autoimmune atrophic gastritis, which may progress to pernicious anemia as the number of gastric parietal cells decreases. These antibodies are present in approximately 80% to 90% of patients with pernicious anemia in the early stages of the disease. However, as the disease progresses, these antibodies decrease in parallel with the progressive loss of gastric parietal cells, so only about half of the people with advanced pernicious anemia have detectable gastric parietal cell antibodies. Therefore, the absence of gastric parietal cell antibodies doesn’t exclude pernicious anemia. Gastric parietal cell antibodies are also not entirely specific to pernicious anemia as they can be detected in other autoimmune disorders (eg, Hashimoto thyroiditis, type 1 diabetes). Low levels of these antibodies can also be found in about 5% of healthy people.

Unlike gastric parietal cell antibodies, antibodies against intrinsic factor are moderately sensitive but highly specific for pernicious anemia, although they can rarely exist in immunological diseases. Because only 50% to 70% of patients with pernicious anemia have intrinsic factor antibodies, the lack of these antibodies cannot exclude pernicious anemia; they are nevertheless so specific to pernicious anemia that their presence effectively confirms the diagnosis. There are two types of intrinsic factor antibodies: (1) blocking antibodies inhibit cobalamin from binding to intrinsic factor, blocking the formation of the "cobalamin-intrinsic factor" complex that is meant to transport cobalamin safely to the small intestine; and (2) binding antibodies bind to the "cobalamin-intrinsic factor" complex and prevent its absorption at the terminal ileum. Binding antibodies exist almost exclusively in those with blocking antibodies, which is why measurement of blocking antibodies is generally the preferred approach for a diagnostic test.

Gastrin testing. Elevated levels of serum gastrin as a consequence of gastric achlorhydria are characteristic of pernicious anemia, and in patients with low serum B12 levels, serum gastrin assays may be useful in identifying those in whom vitamin B12 deficiency is caused by pernicious anemia (183; 190). However, atrophic gastritis and pernicious anemia in patients with type 1 autoimmune polyglandular syndrome usually demonstrate low or normal gastrin levels, probably because of the loss of gastrin-producing cells (101).

Other testing. In the absence of gastric parietal cell or intrinsic factor antibodies, gastroenterology consultation and other diagnostic tests (eg, endoscopy) may be necessary to determine the cause of cobalamin deficiency if a clear and sufficient explanation is not readily evident from the patient's history (eg, a long history of adherence to a vegan diet, nitrous oxide exposure in surgery or recreationally, history of fish tapeworm infection, or a history of bariatric surgery, gastrectomy, or surgical resection of the terminal ileum). Some other exposures (eg, use of proton pump inhibitors, H2-receptor blocking agents, or metformin) might raise suspicion that this was a significant or sufficient cause, but by itself is not sufficient proof that such an exposure actually caused a vitamin B insufficiency.

Management

	• In practice, vitamin B12 supplementation is the appropriate treatment for virtually all forms of vitamin B12 deficiency.
	• Even with prompt treatment with sufficient doses of cobalamin, the neurologic deficits caused by vitamin B12 deficiency are not always reversible.
	• If vitamin B12 deficiency is considered a possible cause of existing neurologic deficits, vitamin B12 replacement therapy should be initiated as soon as possible after blood has been taken for diagnostic tests.
	• Oral vitamin B12 replacement is inexpensive and substantially less costly and more convenient for most patients than parenteral therapy.
	• A Cochrane review of oral versus intramuscular vitamin B12 concluded that oral and intramuscular administration of vitamin B12 were similarly efficacious, although the quality of available supporting evidence was low.
	• Until better data are available, it is prudent to initiate therapy with at least one intramuscular injection of 1000 µg. This could then be followed by several weeks of very high-dose oral therapy (2 mg cobalamin daily). Thereafter, daily doses of 1 mg of cobalamin should maintain adequate body B12 stores, even in cases of pernicious anemia.
	• Whether oral or parenteral maintenance therapy is chosen, it is crucial that efficacy is monitored initially by clinical improvement.
	• Sustained correction of vitamin B12 deficiency should be checked annually by serum vitamin B12, methylmalonic acid, or total homocysteine levels.
	• Pernicious anemia requires lifelong treatment, and studies have shown substantial rates of noncompliance with vitamin B12 supplementation.

In practice, vitamin B12 supplementation is the appropriate treatment for virtually all forms of vitamin B12 deficiency. The optimal dosage and route of administration for cobalamin repletion and ongoing supplementation have been somewhat controversial.

Some of the non-neurologic manifestations of vitamin B12 deficiency, such as glossitis, respond promptly to vitamin B12 repletion (220).

Response of atrophic glossitis to cobalamin repletion

Clinical photographs of atrophic glossitis in two patients with pernicious anemia before and after treatment with intramuscular injection of 2 mg of vitamin B12 every 2 days for 2 weeks. (A) Atrophic glossitis in a patient with...

Even with prompt treatment with sufficient doses of cobalamin, the neurologic deficits caused by vitamin B12 deficiency are not always reversible. Therefore, if vitamin B12 deficiency is considered a possible cause of existing neurologic deficits, vitamin B12 replacement therapy should be initiated as soon as possible after blood has been taken for diagnostic tests. Traditionally, this initial therapy has consisted of four to seven daily parenteral (usually intramuscular) injections of 1 mg of cobalamin or intramuscular injection of 1 mg vitamin B12 at weekly intervals for 1 month (190). The reasoning has been that vitamin B12 stores can be repleted faster and more surely by parenteral administration than by the oral route. This initial therapy is then traditionally followed by monthly injections of 1 mg of cobalamin.

The pharmacologic superiority of parenteral vitamin B12 to oral supplementation with large doses of cobalamin has never been demonstrated.

In the absence of intrinsic factor (eg, from pernicious anemia or gastrectomy), the gut absorbs about 1% of ingested cobalamin, and this appears to be true even in patients with diseases of the ileum. In studies comparing the effect of oral and parenteral cobalamin, large doses (2 to 3 mg) of daily oral B12 appear equally effective to daily parental cobalamin 1 mg in rapidly restoring cobalamin stores and treating the signs of deficiency (173; 106; 30). Even in patients with inflammatory bowel disease affecting the terminal ileum (eg, Crohn disease), oral supplementation of vitamin B12 appears to be effective (67). In children under 2 years of age, an oral dose of 1 mg daily is effective, but 2 mg daily is recommended for repleting children who are older than 6 years of age (19). Oral vitamin B12 replacement is inexpensive and substantially less costly and more convenient for most patients than parenteral therapy (23; 133).

A Cochrane review concluded that oral and intramuscular administration of vitamin B12 were similarly efficacious; however, the quality of available supporting evidence was low (212).

Further, none of the studies cited above included large numbers of patients with neurologic deficits, although significant improvement occurred in the limited number of orally treated patients with such deficits. The neurologic deficits included in these studies tended toward mild sensory phenomena rather than severe myelopathic manifestations. It has specifically not been shown that oral vitamin B12 therapy is as good as parenteral therapy to alleviate neurologic symptoms, particularly in subjects with severe neurologic presentations (217).

Therefore, until better data are available, it is prudent to initiate therapy with at least one intramuscular injection of 1 mg. This could then be followed by one of the following: (1) three to six daily intramuscular injections of 1 mg of cobalamin, (2) intramuscular injection of 1 mg vitamin B12 at weekly intervals for 1 month, or (3) several weeks of very high dose oral therapy (2 mg cobalamin daily). Until more definitive studies are available, severe neurologic presentations should still receive a longer course of parenteral vitamin B12 repletion. Thereafter, daily doses of 1 mg of cobalamin should maintain adequate body B12 stores, even in cases of pernicious anemia.

Sublingual vitamin B12 preparations are increasingly common and are likely as effective as traditional oral supplementation (28).

Whether oral or parenteral maintenance therapy is chosen, it is crucial that efficacy is monitored initially by clinical improvement. Sustained correction of vitamin B12 deficiency should be checked annually by serum vitamin B12, methylmalonic acid, or total homocysteine levels (36). Pernicious anemia requires lifelong treatment, and studies have shown substantial rates of noncompliance with vitamin B12 supplementation (35).

Special considerations

Pregnancy

Maternal vitamin B12 deficiency or borderline deficiency presents two major risks to the developing fetus and infant. First, vitamin B12 deficiency may increase the risk of neural tube defects (99; 166; 199; 16). Second, neurologic and hematologic manifestations of vitamin B12 deficiency may occur in infants breastfed by mothers who have subnormal stores of cobalamin (69; 77; 195; 91). The placenta avidly procures cobalamin for the fetus; consequently, deficiency does not usually manifest until infancy, usually within the first year. Vitamin B12 deficiency in infants may cause irreversible developmental impairment. Infants of mothers on vegan or vegetarian diets are at significant risk of vitamin B12 deficiency unless the mother takes supplementary vitamin B12 (91).

Women with preeclampsia have significantly lower vitamin B12 concentrations than normotensive pregnant women (129).

Anesthesia

The anesthetic agent nitrous oxide irreversibly inactivates cobalamin. Typical neurologic symptoms of vitamin B12 deficiency may develop over a few days or weeks after a single exposure to nitrous oxide in patients with borderline or deficient stores of vitamin B12 (71). This condition should be promptly treated with parenteral vitamin B12 or permanent neurologic damage may occur. Symptoms of vitamin B12 deficiency will also develop in some who chronically use nitrous oxide as a recreational drug, even in the absence of vitamin B12 deficiency (112).

Nitrous oxide dose during labor is a predictor for total homocysteine and may impact the interpretation of total homocysteine analysis in newborn screening (122). In addition, nitrous oxide administration during labor may be a contributing risk factor for infants prone to develop vitamin B12 deficiency (122).

Nitrous oxide-mediated vitamin B12 deficiency may lead to an acute prothrombotic state by elevating homocysteine levels (17). Ninety patients undergoing endarterectomy were randomized to anesthesia with or without nitrous oxide. Postoperative homocysteine levels were higher in the patients randomized to nitrous oxide anesthesia, and ischemic signs on the ECG were significantly more frequent in this group.

Preoperative vitamin supplementation with vitamin B12 can prevent the nitrous oxide-induced elevation in homocysteine levels (18; 98).

Media

References

01: Ahn TB, Cho JW, Jeon BS. Unusual neurological presentations of vitamin B(12) deficiency. Eur J Neurol 2004;11(5):339-41. PMID 15142228
02: Ahrens-Nicklas RC, Whitaker AM, Kaplan P, et al. Efficacy of early treatment in patients with cobalamin C disease identified by newborn screening: a 16-year experience. Genet Med 2017;19(8):926-35. PMID 28151490
03: Ailliet S, Vandenberghe R, Schiemsky T, et al. A case of vitamin B12 deficiency neurological syndrome in a young adult due to late-onset cobalamin C (CblC) deficiency: a diagnostic challenge. Biochem Med (Zagreb) 2022;32(2):020802. PMID 35464742
04: Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 2008;300(15):1774-83. PMID 18854539
05: Akyay A, Soylu E, Ünsal S, Demirol H, Bahçeci S. Hearing status in vitamin B12-deficient children. J Paediatr Child Health 2021;57(7):1060-6. PMID 33600619
06: Alam A, Woo JS, Schmitz J, et al. Structural basis of transcobalamin recognition by human CD320 receptor. Nat Commun 2016;7:12100. PMID 27411955
07: Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299(17):2027-36. PMID 18460663
08: Alhaji JH. Vitamin B12 deficiency in patients with diabetes on metformin: Arab countries. Nutrients 2022;14(10):2046. PMID 35631186
09: Andres E, Federici L. Vitamin B12 deficiency in patients receiving metformin: clinical data. Arch Intern Med 2007;167:721-730. PMID 17420435
10: Annibale B, Lahner E, Fave GD. Diagnosis and management of pernicious anemia. Curr Gastroenterol Rep 2011;13(6):518-24. PMID 21947876
11: Antony AC. Vegetarianism and vitamin B-12 (cobalamin) deficiency. Am J Clin Nutr 2003;78(1):3-6. PMID 12816765
12: Aoyama T, Maezawa Y, Cho H, et al. Phase II Study of a multi-center randomized controlled trial to evaluate oral vitamin B12 treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. Anticancer Res 2022;42(8):3963-70. PMID 35896261
13: Arendt JF, Horváth-Puhó E, Sørensen HT, et al. Plasma vitamin B12 levels, high-dose vitamin B12 treatment, and risk of dementia. J Alzheimers Dis 2021;79(4):1601-12. PMID 33459639
14: Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 2016;101(4):1754-61. PMID 26900641
15: Atay E, Akin M, Ozhan B, Osman O, Karakus YT, Erdogan F. Frequency of hematological findings associated with severe plasma vitamin B12 deficiency in infants and adolescents. Clin Lab 2014;60(4):659-62. PMID 24779301
16: Ayaz R, Asoglu MR. Neural tube defects in eastern Turkey: is low folate status or vitamin B12 deficiency or both associated with a high rate of NTDs? J Matern Fetal Neonatal Med 2020;33(22):3835-40. PMID 31122096
17: Badner NH, Beattie S, Freeman D, Spence JD. Nitrous oxide-induced elevated homocysteine concentrations are associated with increased myocardial ischemia in patients undergoing carotid endarterectomy. Anesth Analg 2000;91:1073-9. PMID 11049886
18: Badner NH, Freeman D, Spence JD. Preoperative oral B vitamins prevent nitrous oxide-induced postoperative plasma homocysteine increases. Anesth Analg 2001;93(6):1507-10. PMID 11726432
19: Bahadir A, Reis PG, Erduran E. Oral vitamin B12 treatment is effective for children with nutritional vitamin B12 deficiency. J Paediatr Child Health 2014;50(9):721-5. PMID 24944005
20: Bahardoust M, Mousavi S, Ziafati H, et al. Vitamin B12 deficiency after total gastrectomy for gastric cancer, prevalence, and symptoms: a systematic review and meta-analysis. Eur J Cancer Prev 2024;33(3):208-16. PMID 37669168
21: Balk EM, Raman G, Tatsioni A, Chung M, Lau J, Rosenberg IH. Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med 2007;167(1):21-30. PMID 17210874
22: Battat R, Kopylov U, Byer J, et al. Vitamin B12 deficiency in inflammatory bowel disease: a prospective observational study. Eur J Gastroenterol Hepatol 2017;23(12)1361-7. PMID 28953003
23: BC Guidelines and Protocols Advisory Committee. Cobalamin (vitamin B12) deficiency: investigation and management. Accessed January 21, 2021. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/bc-guidelines/vitamin-b12. British Columbia: BC Ministry of Health, 2012.
24: Beitzke M, Pfister P, Fortin J, Skrabal F. Autonomic dysfunction and hemodynamics in vitamin B12 deficiency. Auton Neurosci 2002;97(1):45-54. PMID 12036186
25: Bell DS. Nondiabetic neuropathy in a patient with diabetes. Endocr Pract 1995;1(6):393-4. PMID 15251565
26: Bell DS. Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes Obes Metab 2022;24(8):1423-8. PMID 35491956
27: Benbir G, Uysal S, Saltik S, et al. Seizures during treatment of Vitamin B12 deficiency. Seizure 2007;16(1):69-73. PMID 17150378
28: Bensky MJ, Ayalon-Dangur I, Ayalon-Dangur R, et al. Comparison of sublingual vs. intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency. Drug Deliv Transl Res 2019;9(3):625-30. PMID 30632091
29: Bermejo F, Algaba A, Guerra I, et al. Should we monitor vitamin B12 and folate levels in Crohn’s disease patients. Scand J Gastroenterol 2013;48(11):1272-7. PMID 24063425
30: Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clin Ther 2003;25(12):3124-34. PMID 14749150
31: Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88. PMID 16531614
32: Bonafede L, Ficicioglu CH, Serrano L, et al. Cobalamin C deficiency shows a rapidly progressing maculopathy with severe photoreceptor and ganglion cell loss. Invest Ophthalmol Vis Sci 2015;56(13):7875-87. PMID 26658511
33: Bourque DK, Mellin-Sanchez LE, Bullivant G, et al. Outcomes of patients with cobalamin C deficiency: a single center experience. JIMD Rep 2020;57(1):102-14. PMID 33473346
34: Brescoll J, Daveluy S. A review of vitamin B12 in dermatology. Am J Clin Dermatol 2015;16(1):27-33. PMID 25559140
35: Carmel R. The disappearance of cobalamin absorption testing: a critical diagnostic loss. J Nutr 2007;137(11):2481-4. PMID 17951489
36: Carmel R. How I treat cobalamin (vitamin B12) deficiency. Blood 2008;112(6):2214-21. PMID 18606874
37: Carmel R. Holotranscobalamin: not ready for prime time. Clin Chem 2012;58:643-45; author reply 645-6. PMID 22194631
38: Carmel R, Aurangzeb I, Qian D. Associations of food-cobalamin malabsorption with ethnic origin, age, Helicobacter pylori infection, and serum markers of gastritis. Am J Gastroenterol 2001;96:63-70. PMID 11197289
39: Carmel R, Gott PS, Waters CH, et al. The frequently low cobalamin levels in dementia usually signify treatable metabolic, neurologic and electrophysiologic abnormalities. Eur J Haematol 1995;54:245-53. PMID 7789470
40: Centers for Disease Control and Prevention. Neurologic impairment in children associated with maternal dietary deficiency of cobalamin--Georgia, 2001. MMWR Morb Mortal Wkly Rep 2003;52(4):61-4. PMID 12578322
41: Ceravolo R, Cossu G, Bandettini di Poggio M, et al. Neuropathy and levodopa in Parkinson’s disease: evidence from a multicenter study. Mov Disord 2013;28(10):1391-7. PMID 23836370
42: Chatterjee A, Yapundich R, Palmer CA, Marson DC, Mitchell GW. Leukoencephalopathy associated with cobalamin deficiency. Neurology 1996;46(3):832-4. PMID 8618695
43: Chen GY, Tang ZQ, Bao ZX. Vitamin B12 deficiency may play an etiological role in atrophic glossitis and its grading: a clinical case-control study. BMC Oral Health 2022;22(1):456. PMID 36307840
44: Chen M, Shu Y, Li Q, et al. Bacteroides ovatus accelerates metformin-induced vitamin B12 deficiency in type 2 diabetes patients by accumulating cobalamin. NPJ Biofilms Microbiomes 2023;9(1):51. PMID 37488134
45: Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998;55(11):1449-55. PMID 9823829
46: Coelho D, Kim JC, Miousse IR, et al. Mutations in ABCD4 cause a new inborn error of vitamin B12 metabolism. Nat Genet 2012;44(10):1152-5. PMID 22922874
47: Cunha UG, Rocha FL, Peixoto JM, Motta MF, Barbosa MT. Vitamin B12 deficiency and dementia. Int Psychogeriatr 1995;7(1):85-8. PMID 7579024
48: Daniel Y, Freeman S. Not a laughing matter: when nitrous oxide causes functional vitamin B12 deficiency. R I Med J (2013) 2024;107(2):13-5. PMID 38285744
49: Dasari S, Naha K, Prabhu M. An unusual cause for recurrent jaundice in an otherwise healthy male. Australas Med J 2012;5:541-3. PMID 23173018
50: de Lau LM, Smith AD, Refsum H, Johnston C, Breteler MM. Plasma vitamin B12 status and cerebral white-matter lesions. J Neurol Neurosurg Psychiatry 2009;80(2):149-57. PMID 18977824
51: Doan T, Chao JR. A woman with bilateral maculopathy and acquired vitamin B12 deficiency. Eye (Lond) 2014;28(7):905-6. PMID 24788008
52: Dogan M, Ariyuca S, Peker E, et al. Psychotic disorder, hypertension and seizures associated with vitamin B12 deficiency: a case report. Hum Exp Toxicol 2012;31:410-3. PMID 22027500
53: Donnelly S, Callaghan N. Subacute combined degeneration of the spinal cord due to folate deficiency in association with a psychotic illness. Ir Med J 1990;83(2):73-4. PMID 2391215
54: Doscherholmen A, Swaim WR. Impaired assimilation of egg Co 57 vitamin B 12 in patients with hypochlorhydria and achlorhydria and after gastric resection. Gastroenterology 1973;64(5):913-9. PMID 4633664
55: Douaud G, Refsum H, de Jage CA, et al. Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci U S A 2013;110:9523-8. PMID 23690582
56: Edvardsson B, Persson S. Blepharospasm and vitamin B12 deficiency. Neurol India 2010;58(2):320-1. PMID 20508362
57: England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology 2009;72:185-92. PMID 19056666
58: Erol I, Alehan F, Gumus A. West syndrome in an infant with vitamin B12 deficiency in the absence of macrocytic anaemia. Dev Med Child Neurol 2007;49(10):774-6. PMID 17880648
59: Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr 2006;84(2):361-70. PMID 16895884
60: Farhad K, Traub R, Ruzhansky KM, Brannagan TH. Causes of neuropathy in patients referred as “idiopathic neuropathy.” Muscle Nerve 2015. PMID 26561790
61: Fine EJ, Soria E, Paroski MW, Petryk D, Thomasula L. The neurophysiological profile of vitamin B12 deficiency. Muscle Nerve 1990;13(2):158-64. PMID 2179719
62: Fyfe JC, Madsen M, Højrup P, et al. The functional cobalamin (vitamin B12)-intrinsic factor receptor is a novel complex of cubilin and amnionless. Blood 2004;103(5):1573-9. PMID 14576052
63: Gallai V, Caso V, Paciaroni M, et al. Mild hyperhomocyst(e)inemia: a possible risk factor for cervical artery dissection. Stroke 2001;32(3):714-8. PMID 11239192
64: Gao L, Ran X, Liu X, et al. The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: A multicenter cross-sectional study. J Diabetes 2023;15(9):765-76. PMID 37310028
65: Gehrer S, Kern B, Peters T, Christoffel-Courtin C, Peterli R. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study. Obes Surg 2010;20(4):447-53. PMID 20101473
66: Gilsing AM, Crowe FL, Lloyd-Wright Z, et al. Serum concentrations of vitamin B12 and folate in British male omnivores, vegetarians and vegans: results from a cross-sectional analysis of the EPIC-Oxford cohort study. Eur J Clin Nutr 2010;64(9):933-9. PMID 20648045
67: Gomollon F, Gargallo CJ, Muñoz JF, et al. Oral cyanocobalamin is effective in the treatment of vitamin B12 deficiency in Crohn's disease. Nutrients 2017;9(3):308. PMID 28335526
68: Goringe A, Ellis R, McDowell I, et al. The limited value of methylmalonic acid, homocysteine and holotranscobalamin in the diagnosis of early B12 deficiency. Haematologica 2006;91:231-4. PMID 16461308
69: Grattan-Smith PJ, Wilcken B, Procopis PG, Wise GA. The neurological syndrome of infantile cobalamin deficiency: developmental regression and involuntary movements. Mov Disord 1997;12(1):39-46. PMID 8990052
70: Grech V, Vella C, Mercieca V. Temporary myoclonus with treatment of congenital transcobalamin 2 deficiency. Pediatr Neurol 2001;24(1):75-6. PMID 11182287
71: Green R, Kinsella LJ. Current concepts in the diagnosis of cobalamin deficiency. Neurology 1995;45(8):1435-40. PMID 7644036
72: Green R, Miller JW. Vitamin B12 deficiency is the dominant nutritional cause of hyperhomocysteinemia in a folic acid-fortified population. Clin Chem Lab Med 2005;43:1048-51. PMID 16197296
73: Health Quality Ontario. Vitamin B12 and cognitive function: an evidence-based analysis. Ont Heal Technol Assess Ser 2013;13(23):1-45. PMID 24379897
74: Healton EB, Savage DG, Brust JC, Garrett TJ, Lindenbaum J. Neurologic aspects of cobalamin deficiency. Medicine 1991;70(4):229-45. PMID 1648656
75: Hennerici M. Dissociated foveal and parafoveal visual evoked responses in subacute combined degeneration. Arch Neurol 1985;42(2):130-2. PMID 3977638
76: Herrmann W, Schorr H, Purschwitz K, Rassoul F, Richter V. Total homocysteine, vitamin B(12), and total antioxidant status in vegetarians. Clin Chem 2001;47(6):1094-101. PMID 11375297
77: Hinton CF, Ojodu JA, Fernhoff PM, Rasmussen SA, Scanlon KS, Hannon WH. Maternal and neonatal vitamin B12 deficiency detected through expanded newborn screening--United States, 2003-2007. J Pediatr 2010;157:162-3. PMID 20400092
78: Horrany N, Abu Dahoud W, Moallem Y, Hajouj T, Zreik M, Blum A. The effect of metformin on vitamin B12 deficiency and stroke. Isr Med Assoc J 2023;25(2):122-5. PMID 36841981
79: Huemer M, Diodato D, Schwahn B, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis 2017;40(1):21-48.** PMID 27905001
80: Hurley-Kim K, Vu CH, Dao NM, et al. Effect of metformin use on vitamin B12 deficiency over time (EMBER): a real-world evidence database study. Endocr Pract 2023;29(11):862-7. PMID 37611751
81: Huynh DT, Nguyen NT, Do MD. Vitamin B12 deficiency in diabetic patients treated with metformin: a cross-sectional study. PLoS One 2024;19(4):e0302500. PMID 38662670
82: Hygum K, Lildballe DL, Greibe EH, et al. Mouse transcobalamin has features resembling both human transcobalamin and haptocorrin. PLoS One 2011;6(5):e20638. PMID 21655200
83: Jain KK, Malhotra HS, Garg RK, Gupta PK, Roy B, Gupta RK. Prevalence of MR imaging abnormalities in vitamin B12 deficiency patients presenting with clinical features of subacute combined degeneration of the spinal cord. J Neurol Sci 2014;342(1-2):162-6. PMID 24857760
84: Jaiser SR, Winston GP. Copper deficiency myelopathy. J Neurol 2010;257:869-81. PMID 20232210
85: Jaiser SR, Winston GP. Subacute combined degeneration of the spinal cord despite prophylactic vitamin B12 treatment. J Clin Neurosci 2012;19:1607. PMID 22925415
86: Jhunjhnuwala D, Tanglay O, Briggs NE, Yuen MT, Huynh W. Prognostic indicators of subacute combined degeneration from B12 deficiency: a systematic review. PM R 2022;14(4):504-14. PMID 33780172
87: John S, Hoegerl C. Nutritional deficiencies after gastric bypass surgery. J Am Osteopath Assoc 2009;109(11):601-4. PMID 19948694
88: Jung SB, Nagaraja V, Kapur A, Eslick GD. Association between vitamin B12 deficiency and long-term use of acid-lowering agents: a systematic review and meta-analysis. Intern Med J 2015;45(4):409-16. PMID 25583062
89: Kacharava T, Giorgadze E, Janjgava S, Lomtadze N, Taboridze I. Correlation between vitamin B12 deficiency and autoimmune thyroid diseases. Endocr Metab Immune Disord Drug Targets 2023;23(1):86-94. PMID 35761487
90: Kacpura A, Frigeni M, Gunther K, Farach L. Clinical and biochemical outcomes in cobalamin C deficiency with use of high-dose hydroxocobalamin in the early neonatal period. Am J Med Genet A 2022;188(6):1831-5. PMID 35156754
91: Kadiyala A, Palani A, Rajendraprasath S, Venkatramanan P. Prevalence of vitamin B12 deficiency among exclusively breast fed term infants in South India. J Trop Pediatr 2021;67(1):fmaa114. PMID 33346823
92: Kalantari S, Brezzi B, Bracciamà V, et al. Adult-onset CblC deficiency: a challenging diagnosis involving different adult clinical specialists. Orphanet J Rare Dis 2022;17(1):33. PMID 35109910
93: Kalyan GB, Mittal M, Jain R. Compromised vitamin B12 status of indian infants and toddlers. Food Nutr Bull 2020;41(4):430-7. PMID 32873057
94: Kang JH, Irizarry MC, Grodstein F. Prospective study of plasma folate, vitamin B12, and cognitive function and decline. Epidemiology 2006;17(6):650-7. PMID 17028506
95: Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol 2012;37(1):62-4. PMID 22182436
96: Karlsson FA, Burman P, Lööf L, Mårdh S. Major parietal cell antigen in autoimmune gastritis with pernicious anemia is the acid-producing H+, K+-adenosine triphosphatase of the stomach. J Clin Invest 1988;81(2):475-9. PMID 2828428
97: Khattab R, Albannawi M, Alhajjmohammed D, et al. Metformin-induced vitamin B12 deficiency among type 2 diabetes mellitus patients: a systematic review. Curr Diabetes Rev 2023;19(4):1-10. PMID 35440313
98: Kiasari AZ, Firouzian A, Baradari AG, Nia HS, Kiasari SH. The effect of vitamin B12 infusion on prevention of nitrous oxide-induced homocysteine increase: a double-blind randomized controlled trial. Oman Med J 2014;29(3):194-7. PMID 24936269
99: Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993;86(11):703-8. PMID 8265769
100: Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B(12) and folate. Clin Chem 2000;46(8 Pt 2):1277-83. PMID 10926922
101: Koch CA. Gastrin levels in pernicious anemia [letter]. Dtsch Arztebl Int 2009;106(17):290. PMID 19547631
102: Koike T, Kuzuya M, Kanda S, et al. Raised homocysteine and low folate and vitamin B-12 concentrations predict cognitive decline in community-dwelling older Japanese adults. Clin Nutr 2008;27(6):865-71. PMID 18835069
103: Krajcovicova-Kudlackova M, Blazicek P, Kopcova J, Bederova A, Babinska K. Homocysteine levels in vegetarians versus omnivores. Ann Nutr Metab 2000;44(3):135-8. PMID 11053901
104: Kumar N, Gross JB Jr, Ahlskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004;63(1):33-9. PMID 15249607
105: Kumar P, Nagarajan B, Vyas S, Bansal A, Verma S, Sankhyan N. Nutritional recovery batwing dystonia in infantile vitamin b12 deficiency. Mov Disord 2022;37(11):2308-10. PMID 35977076
106: Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998;92(4):1191-8. PMID 9694707
107: Kwok T, Lee J, Law CB, et al. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr 2011;30(3):297-302. PMID 21216507
108: Kwok T, Tang C, Woo J, Lai WK, Law LK, Pang CP. Randomized trial of the effect of supplementation on the cognitive function of older people with subnormal cobalamin levels. Int J Geriatr Psychiatry 1998;13(9):611-6. PMID 9777425
109: Lanska DJ. Historical aspects of the major neurological vitamin deficiency disorders: the water- soluble B vitamins. In: Boller F, Finger S, Tyler KL, etditors. History of Neurology (Handbook of Clinical Neurology. Third series). Vol. 95. Chapter 30. Amsterdam: Elsevier Science Publishing Co, 2010:445-76.** PMID 19892133
110: Lanska DJ, Remler B. Myelopathy among zinc-smelter workers in Upper Silesia during the late 19th century. Neurology 2014;82(13):1175-9. PMID 24688096
111: Larner AJ, Zeman AZ, Allen CM, Antoun NM. MRI appearances in subacute combined degeneration of the spinal cord due to vitamin B12 deficiency [letter]. J Neurol Neurosurg Psychiatry 1997;62(1):99-100. PMID 9010410
112: Layzer RB, Fishman RA, Schafer JA. Neuropathy following abuse of nitrous oxide. Neurology 1978;28(5):504-6. PMID 205816
113: Lee YP, Loh CH, Hwang MJ, Lin CP. Vitamin B12 deficiency and anemia in 140 Taiwanese female lacto-vegetarians. J Formos Med Assoc 2021;120(11):2003-9. PMID 33906782
114: Leleu D, Denimal D. A case of functional vitamin B12 deficiency after recreational nitrous oxide use. Biochem Med (Zagreb) 2024;34(1):010801. PMID 38125615
115: Lemoine M, François A, Grangé S, et al. Cobalamin C deficiency induces a typical histopathological pattern of renal arteriolar and glomerular thrombotic microangiopathy. Kidney Int Rep 2018;3(5):1153-62. PMID 30197982
116: Lerner-Ellis JP, Tirone JC, Pawelek PD, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nat Genet 2006;38(1):93-100. PMID 16311595
117: Levy J, Rodriguez-Guéant RM, Oussalah A, et al. Cardiovascular manifestations of intermediate and major hyperhomocysteinemia due to vitamin B12 and folate deficiency and/or inherited disorders of one-carbon metabolism: a 3.5-year retrospective cross-sectional study of consecutive patients. Am J Clin Nutr 2021;113(5):1157-67. PMID 33693455
118: Lichtheim L. Zur kenntniss der perniziosen anamie. Verhandlungen des Kongresses für innere Medizin 1887;6:84-99.
119: Lindenbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318(26):1720-8. PMID 3374544
120: Lipari Pinto P, Florindo C, Janeiro P, et al. Acquired vitamin B12 deficiency in newborns: positive impact on newborn health through early detection. Nutrients 2022;14(20):4397. PMID 36297083
121: Liu Q, Li S, Quan H, Li J. Vitamin B12 status in metformin treated patients: systematic review. PloS One 2014;9(6):e100379. PMID 24959880
122: Ljungblad UW, Lindberg M, Eklund EA, Saeves I, Bjørke-Monsen AL, Tangeraas T. Nitrous oxide in labour predicted newborn screening total homocysteine and is a potential risk factor for infant vitamin B12 deficiency. Acta Paediatr 2022a;111(12):2315-21. PMID 36029294
123: Ljungblad UW, Paulsen H, Mørkrid L, et al. The prevalence and clinical relevance of hyperhomocysteinemia suggesting vitamin B12 deficiency in presumed healthy infants. Eur J Paediatr Neurol 2021;35:137-46. PMID 34717141
124: Ljungblad UW, Astrup H, Mørkrid L, et al. Breastfed infants with spells, tremor, or irritability: rule out vitamin B12 deficiency. Pediatr Neurol 2022b;131:4-12. PMID 35439713
125: Lombardo M, Franchi A, Biolcati Rinaldi R, et al. Long-term iron and vitamin B12 deficiency are present after bariatric surgery, despite the widespread use of supplements. Int J Environ Res Public Health 2021;18(9):4541. PMID 33922904
126: Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354(15):1567-77. PMID 16531613
127: Malbora B, Yuksel D, Aksoy A, Ozkan M. Two infants with infantile spasms associated with vitamin B12 deficiency. Pediatr Neurol 2014;51(1):144-6. PMID 24810877
128: Malinowski SS. Nutritional and metabolic complications of bariatric surgery. Am J Med Sci 2006;331:219-25. PMID 16617238
129: Mardali F, Fatahi S, Alinaghizadeh M, et al. Association between abnormal maternal serum levels of vitamin B12 and preeclampsia: a systematic review and meta-analysis. Nutr Rev 2021;79(5):518-28. PMID 33001182
130: Marks VJ, Briggaman RA, Wheeler CE Jr. Hyperpigmentation in megaloblastic anemia. J Am Acad Dermatol 1985;12(5 Pt 2):914-7. PMID 3998224
131: Mathew AR, Di Matteo G, La Rosa P, et al. Vitamin B12 deficiency and the nervous system: beyond metabolic decompensation-comparing biological models and gaining new insights into molecular and cellular mechanisms. Int J Mol Sci 2024;25(1):590. PMID 38203763
132: Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis 2011;34(1):127-35. PMID 20632110
133: Masucci L, Goeree R. Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis. Ont Heal Technol Assess Ser 2013;13(24):1-24. PMID 24379898
134: Merola A, Zibetti M, Rizzone MG, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand 2014;129(1):e1-5. PMID 23834498
135: Miller DR, Bloom GE, Streiff RR, LoBuglio AF, Diamond LK. Juvenile "congenital" pernicious anemia. Clinical and immunologic studies. N Engl J Med 1966;275(18):978-83. PMID 5922169
136: Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis 1992;50(1):39-42. PMID 1516378
137: Moore A, Ryan J, Watts M, Pillay I, Clinch D, Lyons D. Orthostatic tolerance in older patients with vitamin B12 deficiency before and after vitamin B12 replacement. Clin Auton Res 2004;14(2):67-71. PMID 15095047
138: Muller T, van Laar T, Cornblath DR, et al. Peripheral neuropathy in Parkinson’s disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013;19:501-7 ; discussion 501. PMID 23453891
139: Naha K, Dasari S, Vivek G, Prabhu M. Vitamin B12 deficiency: an unusual cause for recurrent generalised seizures with pancytopaenia. BMJ Case Reports 2012;2012. PMID 22948998
140: Nalder L, Zheng B, Chiandet G, Middleton LT, de Jager CA. Vitamin B12 and folate status in cognitively healthy older adults and associations with cognitive performance. J Nutr Health Aging 2021;25(3):287-94. PMID 33575718
141: Nardin RA, Amick AN, Raynor EM. Vitamin B(12) and methylmalonic acid levels in patients presenting with polyneuropathy. Muscle Nerve 2007;36(4):532-5. PMID 17623858
142: Natera-Villalba E, Estevez-Fraga C, Sanchez-Herrera FA, et al. Simultaneous acute presentation of generalized chorea and subacute combined degeneration secondary to vitamin B12 deficiency. Parkinsonism Relat Disord 2018;55:2-4. PMID 30220555
143: Nguyen MG, Tronick L, Modirian F, Mardach R, Besterman AD. Neurodevelopmental and neuropsychiatric disorders in cobalamin C disease: a case report and review of the literature. Cold Spring Harb Mol Case Stud 20224;8(2):a006179. PMID 35105663
144: Nielsen MJ, Rasmussen MR, Andersen CB, Nexø E, Moestrup SK. Vitamin B12 transport from food to the body's cells--a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol 2012;9(6):345-54. PMID 22547309
145: Nielsen S, Parkner T, Arendt JF. Vitamin B12 deficiency: correction of P-methylmalonic acid for estimated glomerular filtration rate to improve diagnostic value - a confirmatory study. Scand J Clin Lab Invest 2022;82(4):323-8. PMID 35822404
146: Nilsson K, Isaksson A, Gustafson L, Hultberg B. Clinical utility of serum holotranscobalamin as a marker of cobalamin status in elderly patients with neuropsychiatric symptoms. Clin Chem Lab Med 2004;42(6):637-43. PMID 15259380
147: Noel N, Maigne G, Tertian G, et al. Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. QJM 2013;106(11):1017-22. PMID 23842487
148: Oner T, Guven B, Tavli V, Mese T, Yilmazer MM, Demirpence S. Postural orthostatic tachycardia syndrome (POTS) and vitamin B12 deficiency in adolescents. Pediatrics 2014;133(1): e138-42. PMID 24366986
149: Ozdemir O, Baytan B, Gunes AM, Okan M. Involuntary movements during vitamin B12 treatment. J Child Neurol 2010;25(2):227-30. PMID 19525493
150: Ozer EA, Turker M, Bakiler AR, Yaprak I, Ozturk C. Involuntary movements in infantile cobalamin deficiency appearing after treatment. Pediatr Neurol 2001;25(1):81-3. PMID 11483404
151: Pacchetti C, Cristina S, Nappi G. Reversible chorea and focal dystonia in vitamin B12 deficiency. N Engl J Med 2002;347(4):295. PMID 12140313
152: Pacheco-Quinto J, Rodriguez de Turco EB, DeRosa S, et al. Hyperhomocysteinemic Alzheimer's mouse model of amyloidosis shows increased brain amyloid beta peptide levels. Neurobiol Dis 2006;22(3):651-6. PMID 16516482
153: Padhi S, Sarangi R, Ramdas A, et al. Cutaneous hyperpigmentation in megaloblastic anemia: a five year retrospective review. Mediterr J Hematol Infect Dis 2016;8(1):e2016021. PMID 27158434
154: Pan Y, Liu Y, Guo H, et al. Associations between folate and vitamin B12 levels and inflammatory bowel disease: a meta-analysis. Nutrients 2017;9(4):382. PMID 28406440
155: Park YE, Park SJ, Park JJ, Cheon JH, Kim T, Kim WH. Incidence and risk factors of micronutrient deficiency in patients with IBD and intestinal Behçet's disease: folate, vitamin B12, 25-OH-vitamin D, and ferritin. BMC Gastroenterol 2021;21(1):32. PMID 33478396
156: Paulus MC, Wijnhoven AM, Maessen GC, Blankensteijn SR, van der Heyden MA. Does vitamin B12 deficiency explain psychiatric symptoms in recreational nitrous oxide users? A narrative review. Clin Toxicol (Phila) 2021;59(11):947-55. PMID 34348072
157: Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B(12) deficiency among vegetarians. Nutr Rev 2013;71(2):110-7. PMID 23356638
158: Pedersen GA, Chakraborty S, Steinhauser AL, Traub LM, Madsen M. AMN directs endocytosis of the intrinsic factor-vitamin B(12) receptor cubam by engaging ARH or Dab2. Traffic 2010;11(5):706-20. PMID 20088845
159: Penix LP. Ischemic strokes secondary to vitamin B12 deficiency-induced hyperhomocystinemia. Neurology 1998;51(2):622-4. PMID 9710054
160: Punchai S, Hanipah ZN, Meister KM, Schauer PR, Brethauer SA, Aminian A. Neurologic manifestations of vitamin B deficiency after bariatric surgery. Obes Surg 2017;27(8):2079-82. PMID 28213665
161: Quadros EV. Advances in the understanding of cobalamin assimilation and metabolism. Br J Haematol 2010;148(2):195-204. PMID 19832808
162: Rajabally YA, Martey J. Neuropathy in Parkinson disease: prevalence and determinants. Neurology 2011;77:1947-50. PMID 22049200
163: Ralapanawa DM, Jayawickreme KP, Ekanayake EM, Jayalath WA. B12 deficiency with neurological manifestations in the absence of anaemia. BMC Res Notes 2015;8:458. PMID 26385097
164: Ramanathan S, Karunakaran P, Mohamed KS, Kini R, Thangavel P, Ananthavadivelu M. A rare case of autoimmune gastritis and pernicious anemia associated with vitiligo. J Case Reports 2017;7(2):200-3.
165: Ravakhah K, West BC. Case report: subacute combined degeneration of the spinal cord from folate deficiency. Am J Med Sci 1995;310(5):214-6. PMID 7485226
166: Ray JG, Wyatt PR, Thompson MD, et al. Vitamin B12 and the risk of neural tube defects in a folic-acid-fortified population. Epidemiology 2007;18(3):362-6. PMID 17474166
167: Remacha AF, Souto JC, Piñana JL, et al. Vitamin B12 deficiency, hyperhomocysteinemia and thrombosis: a case and control study. Int J Hematol 2011;93(4):458-64. PMID 21475950
168: Renault F, Verstichel P, Ploussard JP, Costil J. Neuropathy in two cobalamin-deficient breast-fed infants of vegetarian mothers. Muscle Nerve 1999;22(2):252-4. PMID 10024138
169: Reynolds EH, Bottiglieri T, Laundy M, et al. Subacute combined degeneration with high serum vitamin B12 level and abnormal vitamin B12 binding protein. New cause of an old syndrome. Arch Neurol 1993;50(7):739-42. PMID 8323478
170: Riphagen IJ, Minović I, Groothof D, et al. Methylmalonic acid, vitamin B12, renal function, and risk of all-cause mortality in the general population: results from the prospective Lifelines-MINUTHE study. BMC Med 2020;18(1):380. PMID 33298054
171: Rizzo G, Laganà AS, Rapisarda AM, et al. Vitamin B12 among vegetarians: status, assessment and supplementation. Nutrients 2016;8(12):767. PMID 27916823
172: Rodriguez-Gutierrez R, Montes-Villarreal J, Rodríguez-Velver KV, et al. Metformin use and vitamin B12 deficiency: untangling the association. Am J Med Sci 2017;354(2):165-71. PMID 28864375
173: Ross GI, Mollin DL, Cox EV, Ungley CC. Hematologic responses and concentration of vitamin B12 in serum and urine following oral administration of vitamin B12 without intrinsic factor. Blood 1954;9(5):473-88. PMID 13149628
174: Roze E, Gervais D, Demeret S, et al. Neuropsychiatric disturbances in presumed late-onset cobalamin C disease. Arch Neurol 2003;60(10):1457-62.** PMID 14568819
175: Russell JS, Batten FE, Collier J. Subacute combined degeneration of the spinal cord. Brain 1900;23:39-110.
176: Sawada Y, Sakamoto K, Tsukamura A, Sawai C. Vitamin B12 deficiency-induced megaloblastic anemia in a pediatric patient with autism spectrum disorder with a chronically unbalanced diet. Int J Hematol 2024;119(5):613-6. PMID 38526684
177: Sawicki J, Siddha S, Rosen C. Vitiligo and associated autoimmune disease: retrospective review of 300 patients. J Cutan Med Surg 2012;16(4):261-6. PMID 2784519
178: Shaikh SB, Haji IM, Doddamani P, Rahman M. A study of autoimmune polyglandular syndrome (APS) in patients with type1 diabetes mellitus (T1DM) followed up at a teritiary care hospital. J Clin Diagn Res 2014;8(2):70-2. PMID 24701486
179: Shankar DS, Shashikala K, Madala R. Clinical patterns of vitiligo and its associated co morbidities: a prospective controlled cross-sectional study in South India. Indian Dermatol Online J 2012;3(2):114-8. PMID 23130284
180: Sharawat IK, Ramachandran A, Elwadhi A, Tomar A, Panda PK. Nutritional vitamin B12 deficiency-associated Infantile epileptic spasms syndrome: Clinico-neurophysiological presentation, response to treatment, and neurodevelopmental outcome. Seizure 2023;110:93-8. PMID 37331199
181: Sharrief AZ, Raffel J, Zee DS. Vitamin B(12) deficiency with bilateral globus pallidus abnormalities. Arch Neurol 2012;69:769-72. PMID 22332180
182: Siri PW, Verhoef P, Kok FJ. Vitamins B6, B12, and folate: association with plasma total homocysteine and risk of coronary atherosclerosis. J Am Coll Nutr 1998;17(5):435-41. PMID 9791839
183: Slingerland DW, Cardarelli JA, Burrows BA, Miller A. The utility of serum gastrin levels in assessing the significance of low serum B12 levels. Arch Intern Med 1984;144(6):1167-8. PMID 6732375
184: Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. Plos One 2010;5:e12244. PMID 20838622
185: Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999;159(12):1289-98. PMID 10386505
186: Spence JD. Homocysteine: call off the funeral. Stroke 2006;37:282-3. PMID 16397178
187: Spence JD, Yi Q, Hankey GJ. B vitamins in stroke prevention: time to reconsider. Lancet Neurol 2017;16(9):750-60. PMID 28816120
188: Spoelstra-de Man AM, Wagenaar SS, Van der Sluys Veer A, Brouwer CB. Relationship between pernicious anaemia and gastric neuroendocrine cell disorders. Neth J Med 2000;56(2):56-62. PMID 10710942
189: Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013;368:2041-2. PMID 23697526
190: Staff NP. Peripheral neuropathies due to vitamin and mineral deficiencies, toxins, and medications. Continuum (Minneap Minn) 2020;26(5):1280-98.** PMID 33003002
191: Starr JM, Pattie A, Whiteman MC, Deary IJ, Whalley LJ. Vitamin B-12, serum folate, and cognitive change between 11 and 79 years. J Neurol Neurosurg Psychiatry 2005;76(2):291-2. PMID 15654057
192: Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 2005;82:1320-6. PMID 16332666
193: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine Collaborative Group, Armitage JM, Bowman L, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303(24):2486-94. PMID 20571015
194: Suzuki C, Hirai Y, Terui K, Kohsaka A, Akagi T, Suda T. Slowly progressive type 1 diabetes mellitus associated with vitiligo vulgaris, chronic thyroiditis, and pernicious anemia. Intern Med 2004;43(12):1183-5. PMID 15645655
195: Tamura A, Nino N, Yamamoto N, et al. Vitamin B12 deficiency anemia in an exclusively breastfed infant born to an ileum-resected mother. Pediatr Neonatol 2019;60(5):579-80. PMID 31266738
196: Tanc C, Yildiz I. Evaluation of neurodevelopmental screening test scores in children with vitamin B12 deficiency. Neuropediatrics 2024;55(2):97-103. PMID 38122810
197: Tanner SM, Li Z, Perko JD, et al. Hereditary juvenile cobalamin deficiency caused by mutations in the intrinsic factor gene. Proc Natl Acad Sci U S A 2005;102(11):4130-3. PMID 15738392
198: Tanner SM, Sturm AC, Baack EC, Liyanarachchi S, de la Chapelle A. Inherited cobalamin malabsorption: mutations in three genes reveal functional and ethnic patterns. Orphanet J Rare Dis 2012;7:56. PMID 22929189
199: Thompson MD, Cole DE, Ray JG. Vitamin B-12 and neural tube defects: the Canadian experience. Am J Clin Nutr 2009;89(2):697S-701S. PMID 19116334
200: Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B(12) deficiency in patients receiving metformin. Arch Intern Med 2006;166(18):1975-9. PMID 17030830
201: Toh BH, Chan J, Kyaw T, Alderuccio F. Cutting edge issues in autoimmune gastritis. Clin Rev Allergy Immunol 2012;42(3):269-78. PMID 21174235
202: Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291(5):565-75. PMID 14762035
203: Tsai TY, Kuo CY, Huang YC. Serum homocysteine, folate, and vitamin B12 levels in patients with vitiligo and their potential roles as disease activity biomarkers: a systematic review and meta-analysis. J Am Acad Dermatol 2019;80(3):646-54.e5. PMID 30165163
204: Valente E, Scott JM, Ueland PM, Cunningham C, Casey M, Molloy AM. Diagnostic accuracy of holotranscobalamin, methylmalonic acid, serum cobalamin, and other indicators of tissue vitamin B12 status in the elderly. Clin Chem 2011;57:856-63. PMID 21482749
205: Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009;67(11):376-87. PMID 20009114
206: Verhoef P, Hennekens CH, Malinow MR, Kok FJ, Willett WC, Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994;25(10):1924-30. PMID 8091435
207: VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke - in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9(9):855-65. PMID 20688574
208: Vogiatzoglou A, Refsum H, Johnston C, et al. Vitamin B12 status and rate of brain volume loss in community-dwelling elderly. Neurology 2008;71(11):826-32. PMID 18779510
209: von Schenck U, Bender-Gotze C, Koletzko B. Persistence of neurological damage induced by dietary vitamin B-12 deficiency in infancy. Arch Dis Child 1997;77(2):137-9. PMID 9301352
210: Voukelatou P, Vrettos I, Kalliakmanis A. Neurologic symptoms as the only manifestation of B12 deficiency in a young patient with normal hematocrit, MCV, peripheral blood smear and homocysteine levels. Oxf Med Case Reports 2016;2016(12):omw091. PMID 28031855
211: Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid and vitamin B-12 supplementation to prevent cognitive decline in community-dwelling older adults with depressive symptoms--the Beyond Ageing Project: a randomized controlled trial. Am J Clin Nutr 2012;95(1):194-203. PMID 22170358
212: Wang H, Li L, Qin L, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2018;15(3):CD004655. PMID 29543316
213: Wang HX, Wahlin A, Basun H, Fastbom J, Winblad B, Fratiglioni L. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 2001;56(9):1188-94. PMID 11342684
214: Warendorf JK, van Doormaal PT, Vrancken AF, et al. Clinical relevance of testing for metabolic vitamin B12 deficiency in patients with polyneuropathy. Nutr Neurosci 2022;25(12):2536-46. PMID 34693890
215: Whyte AF, Jones DL, Dreyer MD. Vitamin B12 deficiency causing hyperhomocysteinaemia and cerebral venous sinus thrombosis. Intern Med J 2012;42:601-3. PMID 22616971
216: Wirthensohn M, Wehrli S, Ljungblad UW, Huemer M. Biochemical, nutritional, and clinical parameters of vitamin B12 deficiency in infants: a systematic review and analysis of 292 cases published between 1962 and 2022. Nutrients 2023;15(23):4960. PMID 38068819
217: Wolffenbuttel BH, Wouters HJ, Heiner-Fokkema MR, van der Klauw MM. The many faces of cobalamin (vitamin B12) deficiency. Mayo Clin Proc Innov Qual Outcomes 2019;3(2):200-14. PMID 31193945
218: Wong CW, Leung CS, Leung CP, Cheng JN. Association of metformin use with vitamin B12 deficiency in the institutionalized elderly. Arch Gerontol Geriatr 2018;79:57-62. PMID 30114554
219: Wood WD, Elmaghrabi A, Gotway G, Wolf MT. The roles of homocysteinemia and methylmalonic acidemia in kidney injury in atypical hemolytic uremic syndrome caused by cobalamin C deficiency. Pediatr Nephrol 2022;37(6):1415-8. PMID 34854955
220: Wu YH, Hwang M-J, Lee Y-P, Chiang C-P. Atrophic glossitis in pernicious anemia patients can be treated to normal in two weeks by intramuscular injection of vitamin B12. J Dent Sci 2020;15(4):558-9. PMID 33505632
221: Xu X, Liu Y, Xiong X, et al. Diagnostic value of oral "beefy red" patch combined with fingertip blood mean corpuscular volume in vitamin B12 deficiency. BMC Oral Health 2022;22(1):273. PMID 35790943
222: Yan MK, Khalil H. Vitamin supplements in type 2 diabetes mellitus management: a review. Diabetes Metab Syndr 2017;11 Suppl 2:S589-95. PMID 28420574
223: Yang DT, Cook RJ. Spurious elevations of vitamin B12 with pernicious anemia. N Engl J Med 2012;366(18):1742-3. PMID 22551146
224: Yang W, Cai XL, Wu H, Ji L. Associations between metformin use and vitamin B12 level, anemia and neuropathy in patients with diabetes: a meta-analysis. J Diabetes 2019;11(9):729-43. PMID 30615306
225: Yavuz H. Vitamin B12 deficiency and seizures. Dev Med Child Neurol 2008;50(9):720. PMID 18754925
226: Yoo JH, Chung CS, Kang SS. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29(12):2478-83. PMID 9836754
227: Yu Y, Ling S, Shuai R, et al. Clinical features and outcomes of patients with cblC type methylmalonic acidemia carrying gene c.609G>A mutation. Zhejiang Da Xue Xue Bao Yi Xue Ban 2021;50(4):436-43. PMID 34704411
228: Zhang CE, Wei W, Liu YH, et al. Hyperhomocysteinemia increases beta-amyloid by enhancing expression of gamma-secretase and phosphorylation of amyloid precursor protein in rat brain. Am J Pathol 2009;174(4):1481-91. PMID 19264913
229: Zhuo JM, Pratico D. Acceleration of brain amyloidosis in an Alzheimer's disease mouse model by a folate, vitamin B6 and B12-deficient diet. Exp Gerontol 2010;45(3):195-201. PMID 20005283

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Douglas J Lanska MD MS MSPH

Dr. Lanska of the University of Wisconsin School of Medicine and Public Health and the Medical College of Wisconsin has no relevant financial relationships to disclose.
See Profile

Former Authors

Patrick J Bosque MD
Ryan Jacobson MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Subacute combined degeneration of spinal cord in diseases classified elsewhere: G32.0

Deficiency of other specified B group vitamins: E53.8
ICD-11: Vitamin B12 deficiency: 5B5F

Other specified degenerative myelopathic disorders: 8B44.Y
OMIM: Imerslund-Gräsbeck syndrome 1: # 261100

Imerslund-Gräsbeck syndrome 2: # 618882

Intrinsic factor deficiency: # 261000

Transcobalamin II deficiency: # 275350

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Vitamin B12 deficiency

Associated Disorders

Alcohol-tobacco amblyopia
Cerebral vascular disease
Dementia
Depression
Developmental delay
- Folate deficiency
- Gastric resection
- Glossitis
- Imerslund-Grasbeck syndrome
- Malabsorption
- Megaloblastic anemia
- Myelopathy
- Optic neuropathy
- Pernicious anemia
- Polyneuropathy
- Regional enteritis
- Subacute combined degeneration of the spinal cord

Differential Diagnosis

conditions that present with a subacute to chronic neuropathy or myelopathy
multiple sclerosis
HTLV-1 associate myelopathy
Lyme disease
neurosyphilis
- HIV
- copper deficiency
- folate deficiency

Also Relevant

Crohn disease: neurologic manifestations
Copper deficiency myeloneuropathy
Folic acid deficiency
Hyperhomocysteinemia
Methylmalonic acidemia
- Nutrition and the brain
- Nutrition-related peripheral neuropathies
- Toxic and nutritional deficiency optic neuropathies

Clinical Categories

General Neurology

	• In at-risk individuals, vitamin B12 deficiency can be prevented through oral supplementation with the vitamin.
	• Vitamin B12 deficiency in pregnant and breastfeeding women needs to be recognized and corrected because of the potential for irreversible neurologic injury to the child.

Vitamin B12 deficiency

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Table 1. Age-Related Clinical Presentations of Remethylation Disorders

Table 2. Conditions That Mimic Intracellular Disorders of Remethylation

Table 3. Differential Diagnosis of Inborn Errors of Metabolism Presenting with Hyperhomocysteinemia

Table 4. Representation of the Cobalamin Defects Associated with Hyperhomocysteinaemia, the Respective Enzymatic/Incorporations Tests Available and the Genes Involved in these Diseases

Table 5. Main Complications According to System in Remethylation Disorders

Table 6. Recommended Treatment of Remethylation Disorders

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

Brain death/death by neurologic criteria

Outpatient rehabilitation of chronic neurologic conditions

This is an article preview.
Start a Free Account
to access the full version.